Fibroblastikasvutekijäreseptorin inhibointi FGFR3:TACC3 fuusio positiivisissa glioblastoma soluissa by Mäntylä, Sonja Christina
  
 
 
 
 
 
 
 
SONJA MÄNTYLÄ  
INHIBITION OF FIBROBLAST GROWTH FACTOR RECEPTOR IN 
FGFR3:TACC3 FUSION POSITIVE GLIOBLASTOMA CELLS 
 
Master of Science thesis 
 
 
 
 
 
 
Examiner: prof. Minna Kellomäki  
Examiner and topic approved by the 
Faculty Council of the Faculty of Bio-
medical Sciences and Engineering 
on 31th May 2017 
 
  
1 
ABSTRACT 
SONJA MÄNTYLÄ: Inhibition of fibroblast growth factor receptor in 
FGFR3:TACC3 fusion positive glioblastoma cells 
Tampere University of technology 
Master of Science Thesis, 72 pages, 3 Appendix pages 
December 2017 
Master’s Degree Programme in Biotechnology 
Major: Tissue Engineering 
Examiner: Professor Minna Kellomäki 
 
Keywords: brain tumor, glioblastoma multiforme, fibroblast growth factor recep-
tor, FGFR3:TACC3, gene fusion, JNJ-42165279 
 
Glioblastoma multiforme is the most common of adult primary brain tumors. It is 
a highly aggressive form of diffuse gliomas and with current treatments median 
life expectancy of patients with glioblastoma is approximately 14 months. Resent 
research of genetic and molecular changes in glioblastoma has provided new 
insight on disease initiation and progression. Fibroblast growth factor receptor 3 
gene fusion with transforming acidic coiled coil 3 (FGFR3:TACC3) was found in 
subset of glioblastomas and has been shown to increase proliferation and an-
chorage independent growth of tumor cells. It is known to be mutually exclusive 
with other growth factor receptor alterations so it seems to be providing alterna-
tive pathway for tumor formation. However, FGFR3:TACC3 is usually not one of 
the initiating alterations in glioblastoma. Inhibition of FGFR in fusion positive tu-
mors has shown promising results in vitro and in preclinical studies.  
 
The aim of this study was compare cellular mechanisms between SNB19 glio-
blastoma cells that had been stably transfected with FGFR3:TACC3 fusion vec-
tor, FGFR3 vector or empty plasmid vector. Proliferation, migration, colony for-
mation and survival of these overexpressed cell lines were compared. Effect of 
pan-FGFR tyrosine kinase inhibitor JNJ-42165279 to same cellular mechanisms 
in these different overexpression cell lines was also assessed. Furthermore, 
downstream effects of FGFR3:TACC3 and FGFR3 expressing cells to inhibition 
and stimulation with fibroblast growth factor was analyzed at protein level.   
 
In these experiments, FGFR3:TACC3 overexpressed cells showed increased 
proliferation and FGFR3 overexpressed cells decreased proliferation compared 
to the control cells. FGFR3 expressing cells had also lowered colony forming ca-
pability. Inhibition of FGFR in these overexpressing cells showed decrease of 
proliferation in fusion positive cells. Inhibition had no significant effects on other 
cellular mechanisms. Phosphorylation of FGFR was decreased by inhibition in 
both FGFR3:TACC3 and FGFR3 overexpressed cell lines. 
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Glioblastoma multiforme on yleisin aikuisilla esiintyvä primaarinen aivokasvain. 
Se on hyvin aggressiivinen diffuusi glioman muoto ja nykyisillä hoitomenetelmillä 
glioblastoma potilaiden elinajanodotteen mediaani on noin 14 kuukautta. Tutki-
mus glioblastoman geneettisistä ja molekulaarisista muutoksista on tuonut uutta 
tietoa taudin synnystä ja etenemisestä. Fibroblastikasvutekijäreseptori 3 geenin 
fuusion TACC3:n kanssa löydettiin osasta glioblastomia ja sen on näytetty lisää-
vän solujen proliferaatiota sekä kasvua alustalla, johon ne eivät voi kiinnittyä. Sen 
on näytetty esiintyvän kasvaimissa, joissa ei ole muiden kasvutekijä reseptorei-
den muutoksia, joten se vaikuttaa tarjoavan vaihtoehtoisen reitin kasvaimen muo-
dostukselle. FGFR:n inhibointi fuusio positiivisissa kasvaimissa on osoittanut lu-
paavia tuloksia sekä in vitro, että alustavissa kliinisissä kokeissa.   
 
Tämän tutkimuksen tavoite oli tutkia eroja SNB19 glioblastoma solulinjalla, johon 
oli transfektoitu FGFR3:TACC3 vektori, FGFR3 vektori ja tyhjä plasmidi vektori. 
Solulinjojen proliferaatiota, migraatiota, kolonnien muodostus kyvyä ja selviyty-
mistä vertailtiin. Pan-FGFR tyrosiini kinaasi inhibiittorin JNJ-42165279 vaikutusta 
samoihin solumekanismeihin arvoitiin myös eri yliekspressiosolulinjoilla. Lisäksi 
inhiboitujen ja fibroblasti kasvutekijällä stimuloitujen solujen FGFR3:TACC3 ja 
FGFR3 ilmentymisen vaikutuksia signalointi reitteihin yritettiin selvittää proteiini 
tasolla.   
 
Näissä tutkimuksissa havaittiin FGFR3:TACC3 yliekspressiosolujen kasvavan 
nopeammin ja FGFR3 yliekspressiosolujen puolestaan kasvavan hitaammin 
kontrollisoluihin verrattuna. FGFR3 ilmentävillä soluilla oli myös alhaisempi ko-
lonnien muodostus kyky. FGFR:n inhibointi yliekspressiosolulinjoilla hidasti fuu-
sio positiivisten solujen kasvua. Inhibointi ei vaikuttanut merkittävästi muihin tut-
kittuihin solumekanismeihin. FGFR:n fosforylaatio väheni inhibition vaikutuksesta 
sekä FGFR3:TACC3, että FGFR3 yliekspressio solulinjoilla.  
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1. INTRODUCTION 
Glioblastoma (GBM, Glioblastoma multiforme) is the most malignant and most fre-
quently diagnosed primary brain tumor in adult patients. GBM is a diffuse glioma that 
can infiltrate the surrounding tissues. Most of the GBM are primary tumors but it can also 
develop from a lower grade glioma. (Wilson et al. 2014) Prevalence of GBM in Europe 
and North America is approximately 3-4 new patients for 100 000 people in one year 
(Louis et al. 2007). Usually patients suffering from GBM are between ages 45 to 75, but 
it can be found at any age. It is more common on males, but is found in both genders. 
(Ray 2010) 
Standard treatment for glioblastoma includes surgery, radiation and chemotherapy, but 
even with treatment the survival rate of patients is only approximately 14 months (Stupp 
et al., 2009). Unsuccessful treatment of GBM is due to the high proliferation capability, 
invasive nature and multiple forms it can take. Research on genetic and molecular alter-
ations resulting in formation and progression of GBM is hopefully in the future leading 
to specific targeted therapies as a treatment for this devastating disease. (Marumoto & 
Saya, 2012)  
Fusion genes are hybrids of two rearranged genes that have fused together. Fibroblast 
growth factor receptor fusions have been found from many cancers including GBM, pros-
tate, lung, breast and bladder cancer. FGFR can fuse with different partner genes creating 
multiple different fusion genes in different cancers. FGFR3:TACC3 (TACC, transform-
ing acidic coiled-coil containing protein 3) fusion was found in approximately 5 % of 
GBMs (Dienstmann et al., 2014). In earlier studies this fusion has been shown to be on-
cogenic since it is increasing proliferation and anchorage independent growth of a tumor 
cells as well as promoting cell transformation and increasing aneuploidy (Parker et al., 
2013; Singh et al., 2012).  
Inhibition of FGFR3 in fusion positive glioblastoma is interesting treatment approach, 
since normal brain has low expression of FGFR3. Therefore, inhibition of FGFR3 through 
cerebral fluid might cause only few neurological side effects. (Parker, Engels, Annala, & 
Zhang, 2014) Several small molecule tyrosine kinase inhibitors for FGFR inhibition have 
been developed and they have shown significant responses in fusion positive tumors at 
animal studies and preliminary clinical trials (Di Stefano et al., 2015; Tabernero et al., 
2015).  
Purpose of this study was to evaluate effects of overexpression of FGFR3:TACC3 and 
FGFR3 on cellular mechanisms in glioblastoma cell line. Proliferation, migration, colony 
formation and survival of these cells was assessed with different functional tests in vitro. 
Furthermore, inhibition of FGFR and its effect on cellular mechanisms was investigated. 
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Aim was to see whether our cell model behave similarly as those studied earlier by Parker 
et al (2013) and to evaluate if these cells could be used as a model for FGFR3:TACC3 
fusion. Also, we wanted to gain better understanding on oncogenic effect of 
FGFR3:TACC3 fusion and on cellular responses that are induced by the inhibition of 
FGFR3 in fusion positive cells. Earlier studies have shown fusion to be promoting cell 
proliferation and anchorage independent growth, but other cell mechanism that might be 
enhanced by fusion have not yet been evaluated.  
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2. GLIOBLASTOMA  
Cancer formation is believed to be process with multiple steps that includes several on-
cogenic alterations that drive transformation of normal cells into more malignant cell. 
Tumorigenesis begins when a single cell starts to divide abnormally due to changes in its 
DNA and forms a population of tumor cells. Tumor progression continues when cells go 
through additional genetic alterations and some cells gain selective advantage with supe-
rior growth, survival and invasion abilities. (Cooper 2000)  
Hanahan & Weinberg (2000) suggested that similar molecular mechanisms lead to pro-
gression of cancer and listed hallmarks of cancer similar to all cancer types. These hall-
marks are shown in Figure 1. According to their research most if not all cancer cells can 
produce their own growth signals, avoid growth-inhibitory signals from suppressor cells, 
acquire resistance to apoptotic signals, replicate endlessly, develop angiogenesis inducing 
capabilities and invade other tissues and therefore form metastases and these were re-
ferred as hallmarks of cancer. (Hanahan & Weinberg, 2000)  
 
Figure 1. Hallmarks of cancer suggested in 2000 (left image) and additional emerg-
ing hallmarks of cancer suggested in 2011 with addition of two enabling charac-
teristics (right image) (Hanahan & Weinberg, 2011) 
Later due to a progress in research Hanahan & Weinberg (2011) added two additional 
hallmarks; cancer cells can alter cellular metabolism to support cancer proliferation and 
escape the effects of immune defense. Furthermore, they named two characteristics that 
enable and facilitate these hallmarks. Genomic instability allows mutations to alter cells 
more easily and inflammation promoted by tumor cells can support hallmark abilities. 
(Hanahan & Weinberg, 2011)  
2.1 Cells of central nervous system 
Brain tissue consist of neurons, which convey electrical stimuli to the target cells and glial 
cells, which are supporting cells of the nervous system. Neurons consist of dendrites, 
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soma and axon. Dendrites collect the signal from other neurons or cells and pass the signal 
to the cell body soma, from where one axon delivers the signal further to the central nerv-
ous system (CNS, central nervous system). Glial cells have many important functions in 
the nervous system. Glial cells release gliotransmitters that participate in modulation of 
synaptic efficiency of neurons and neuronal excitability (Newman, 2015). They work as 
supporting cells of the CNS, help to speed up the signal delivery and maintain the home-
ostasis of the brain. (Brodal 2004)  
 
Figure 1. Glial cells of central nervous system A. Astrocyte B. Oligodendro-
cyte C. Microglia.  Number 1 shows the capillary of the brain. (Valenta et 
al., 2012) 
Glial cells are divided to three groups: astroglia or astrocytes, oligodendroglia or oli-
godendrocytes and microglia (Figure 1). Some infrequent types of glial cells can also be 
found in the CNS: ependyma cells covering the cavities of CNS, Müller cells found at the 
retina, Bergman cells found from the cerebellum and pituicytes found from the pituitary 
gland (Brodal 2004). Astrocytes and oligodendrocytes are large cells that arise from the 
neural tube. Astrocytes work as insulators of specific neurons. They also form the blood-
brain barrier and take part to the regulation of different functions in the brain. Oligoden-
drocytes create myelin sheets around axons thus working as insulators around axons. Mi-
croglia are smaller cells that work as macrophages of CNS and are especially important 
after trauma or during diseases of CNS. (Valenta et al. 2012) 
2.2 Formation of Glioblastoma Multiforme 
Gliomas are primary tumors found in CNS that resemble glial cells. There are two types 
of gliomas; diffuse gliomas have ability to infiltrate other parts of the brain tissue and 
circumscribed growth gliomas do not have that ability. (Aldape et al. 2015) Diffuse glio-
mas can be classified by their histology and cells of origin as astrocytomas, oligodendro-
gliomas and oligoastrocytomas. Usually they consist of cells that resemble different types 
of CNS cells. They are the most common types of tumors in CNS. (Marumoto & Saya 
2012) 
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Gliomas are graded according the World Health Organization (WHO) grading system to 
grades I–IV depending on how malignant tumor is (Marumoto & Saya 2012). Glioblas-
toma is the most malignant form of diffuse gliomas and it is graded as a grade IV tumor. 
(Louis et al. 2007). Grade IV tumors are the most aggressive form of brain tumors and 
they have the ability to invade different parts of the brain, which is why they are difficult 
to remove by surgery. Also grade II and III tumors are diffusive and can infiltrate sur-
rounding tissues. Grade I tumors are much less aggressive than other grades. (Ray 2010, 
Chapter 2) In 2016 WHO updated their grading system by adding some tumor type spe-
cific molecular changes seen in brain tumors to the classification. WHO grading system 
for selected tumors of CNS is shown in table 1. (Louis et al., 2016)  
Table 1.  WHO grading system for selected tumors of CNS (Louis et al., 2016) 
 
There are two forms of GBM, primary and secondary form. Primary form is more general 
with older patients and secondary with under 45-year-old patients. Primary GBM is more 
common since approximately 90 % of GBM are primary. (Wilson et al. 2014) Secondary 
GBM develops from lower grade diffuse astrocytomas and primary tumor occurs de novo 
meaning there is no earlier symptoms or sign of lower grade glioma (Marumoto & Saya 
2012).  Classifying and treatment of GBM is challenging because it can take many dif-
ferent forms like small cell, large cell, spindle cell or gemistocytic forms. (Ray 2010)  
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2.3 GBM treatment and prevalence 
Glioblastoma is aggressive tumor with high vascular proliferation, necrosis and pleo-
morphism (cell sizes and shapes may vary) (Marumoto & Saya 2012). Standard treatment 
for GBM is first surgery and then radiation therapy alone or together with chemotherapy, 
usually temozolomide (Nicolaidis 2015). Despite the treatment, patient survival with 
GBM is low and median life expectancy after the diagnosis is 12 to 14 months. GBM has 
a poor response on chemotherapy. All grade II–IV brain tumors including GBM are dif-
fusive by nature that makes them impossible to get the whole tumor removed with surgery 
(Aldape et al. 2015). Often tumor is located in the areas of brain that control speech, motor 
functions or senses, which makes the surgery even more difficult (Davis, 2016). Combi-
nation treatment with radiation and temozolomide has shown significantly better survival 
results, with median of 2,5 months longer survival (Stupp et al., 2005). Radiation com-
bined with temozolomide is therefore widely used all over the world.  
Other therapies including radioimmunotherapy, iodine-125 brachytherapy, stereotactic 
radiosurgery and hyperfractionation have also been tried as a treatment for GBM, but 
results of these treatments have not shown better survival of the patients. Treatments tar-
geting different molecular changes like inhibitors of tyrosine kinases and signal transduc-
tion are in clinical trials but also these have failed to provide significant survival benefit 
in GBM patients. (Davis, 2016)  
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3. MOLECULAR MECHANISM OF GBM 
Gliomagenesis is derived by many molecular and genetic changes that will alter signaling 
pathways leading to the growth and progression of glioblastoma. Also, some epigenetic 
changes have been observed in glioblastoma and DNA methylation is most studied of 
those changes. Different changes in methylation of genes related to the control of cell 
cycle, suppression of tumor progression, repairing DNA and inhibiting apoptosis for ex-
ample have been observed. Of genetic changes, alterations of growth factor tyrosine ki-
nase pathways are one of the key factors in gliomagenesis. (Crespo et al., 2015) Some of 
the genetic alterations frequently seen in GBM are introduced in this chapter. 
3.1 Overexpression of growth factor receptors in GBM 
Epidermal growth factor receptor (EGFR, epidermal growth factor receptor) is expressed 
in brain during the whole brain development taking part in proliferation, differentiation, 
migration and survival of cells of the CNS (Nicholas et al., 2006). EGFR gene is fre-
quently amplified, mutated or rearranged in GBM. Highly observed activity of EGFR 
signaling pathway can be caused by overexpression of receptor and its ligand or by con-
stitutive activation of a receptor even without the ligand binding due to mutation or by 
genomic amplification of EGFR (Huang, Xu, & White, 2009). These will lead to uncon-
trolled phosphorylation of EGFR making it oncogenic in gliomas. (Hatanpaa et al., 2010)  
Platelet derived growth factor receptor (PDGFR, platelet derived growth factor receptor) 
and its ligand are often overexpressed in GBM. Alterations of PDGFR are believed to be 
early events in gliomagenesis followed by changes in other parts of the signaling path-
ways. (Crespo et al., 2015) Amplifications and rearrangements of PDGFR as well as over-
expression of its ligand have been characterized by the Cancer Genome Atlas (TCGA, 
the Cancer Genome Atlas) (Verhaak et al., 2010). Results of animal studies have sug-
gested that alteration of PDGFR could be oncogenic driver for converting neural stem 
cells to tumor cells (Rheinbay et al., 2013).  
Tyrosine protein kinase MET, (MET, tyrosine protein kinase) also known as hepatocyte 
growth factor receptor is also frequently or overexpressed in GBM and also in many other 
cancers. MET overexpression is suggested to promote malignancy of GBM and to pro-
mote the cancer progression if EGFR is inhibited which could explain treatment re-
sistance of GBM to inhibition (Xu et al., 2012). MET overexpression is also found to be 
corresponding to aggressiveness of gliomas since it is only seen in higher grade gliomas 
and GBM. (Kwak et al., 2015) Amplifications of MET are also frequently seen in glio-
blastoma. Most of the tumors harboring MET amplification are shown to harbor also 
EGFR alterations. (Brennan et al., 2013)   
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Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that participates to 
cell proliferation, angiogenesis, migration and survival. FGFRs have recently been un-
covered as oncogenic drivers in many cancers and are studied as a potential target for 
inhibition therapies. Subset of GBMs was found to harbor fusion of FGFR1 or FGFR3 
with transforming acidic coiled coil (TACC, transforming acidic coiled coil). 
(Dienstmann et al., 2014) Structure and signaling of FGFR and its fusion are explained 
more specifically in chapter 4.  
3.2 IDH mutation in GBM 
Isocitrate Dehydrogenases (IDH) are family of isoenzymes IDH1, IDH2 and IDH3 that 
are encoded by five genes. IDH3 is found from the matrix of mitochondria and catalyzes 
transformation of isocitrate to -ketoglutarate (-KG, -ketoglutarate) in citric acid cy-
cle, converting NAD+ (NAD, Nicotinamide adenine dinucleotide) to NADH at the same 
time. While IDH3 reactions are irreversible, IDH1 and IDH2 catalyze reversible oxidative 
decarboxylation reactions outside of citric acid cycle. They are also transforming iso-
citrate to -KG producing NADPH (NADPH, Nicotinamide adenine dinucleotide phos-
phate) from NADP+ at the same time. IDH1 is located in peroxisomes found from cyto-
plasm and its expression is highest in liver cells. It takes part in glucose sensing and me-
tabolism of lipids. IDH2 is found from mitochondria, where it regulates citric acid cycle. 
It is highly expressed in muscle and heart tissue as well as activated lymphocytes. IDHs 
are also thought to maintain redox state in the cells and therefore defending cells against 
oxidative stress. (Cohen, Holmen, & Colman, 2013; Reitman & Yan, 2010)  
IDH1/2 are known to be mutated in most of the low-grade gliomas but also in secondary 
higher-grade gliomas. Amino acid residue 132 is mutated in all IDH1 mutations in glio-
mas and approximately 85 % of those contain a heterozygous missense mutation changing 
arginine to histidine. The mutation prevents IDH1 binding to isocitrate, because mutation 
happens in the active site of the enzyme. When isocitrate cannot bind to IDH1, levels of 
-KG and NADPH are reduced in the cells and cells are more sensitive to effects of re-
active oxygen species. (Cohen et al., 2013) IDH2 mutation happens at residue 172 exactly 
like mutation at residue 132 in IDH1. Mutation of residue 140 has also been found in 
IDH2, but it has not been seen in gliomas. (Reitman & Yan, 2010)  
IDH1 and IDH2 mutations are mutually exclusive in gliomas and they are seen early on 
in tumor progression. Approximately 80 % of grade II-III gliomas and secondary GBMs 
harbor IDH1 mutation, some are harboring IDH2 mutation and small subset that harbor 
wild type IDH (Cohen et al., 2013). It has been shown that while mutation of IDH is 
reducing -KG in the cells it is also producing more 2-hydroxyglutarate (2-HG). It is now 
thought that productions of 2-HG could be the initiating oncogenic incident. (Yen & 
Schenkein, 2011)  
15 
IDH1 mutation is more common in GBM than IDH2. IDH1 mutation is often found in 
secondary GBM and usually not found in primary GBM Therefore, mutation on IDH1 is 
shown to be reliable genetic marker for secondary glioblastoma since in 95% of the pa-
tient’s mutation status of IDH1 corresponds to clinical diagnosis.  (Nobusawa et al., 2009; 
Oh et al., 2016) In the treatment of gliomas IDH mutation is important prognostic factor 
since lower grade gliomas that harbor wild type IDH are behaving almost as aggressively 
as GBMs. Tumors with IDH mutation show better response to chemotherapy than IDH 
wild type tumors, so mutation is also thought to be predictive treatment marker. (Karsy 
et al., 2017)      
In 2016 WHO classification system of brain tumors was updated so that the clinical eval-
uation of tumors previously done histologically should now include molecular changes 
seen in tumors. IDH mutation is one of the main molecular markers for classification of 
gliomas and its expression is histologically evaluated in all tumor samples. Figure 2 
shows diagram for classification of gliomas, where IDH status is the defining the charac-
terization. (Louis et al., 2016) 
 
Figure 2.  Classification of gliomas after 2016 update on WHO classification (Louis 
et al, 2016).  
IDH mutation has shown to be mutually exclusive with FGFR3:TACC3 fusion. Fusion 
seems to be present only in subset of lower grade gliomas with IDH wild type as well as 
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IDH wild type GBMs. Brain tumors with IDH wild type have significantly poorer prog-
nosis than IDH mutated tumors suggesting that FGFR3:TACC3 fusion might be one 
cause increased tumor aggressiveness. (Di Stefano et al., 2015)  
3.3 Other genetic alterations frequently seen in GBM 
Phosphatase and Tensin Homolog Deleted from Chromosome 10 (PTEN, Phosphatase 
and Tensin Homolog Deleted from Chromosome 10) is a tumor suppressor gene that is 
mutated in many different cancer types. It is more frequently mutated in higher grade 
tumors including GBM. PTEN does not need to be mutated at the initiation of tumor but 
is thought to be important factor in progression of tumor to more malignant form. PTEN 
is known to be negative regulator of PI3K signaling pathway and wild type PTEN has the 
ability to suppress tumor progression of glioma cells (Fan et al., 2002). In GBM mutation 
of PTEN and loss of heterozygosity of chromosome 10 (LOH10q, loss of heterozygosity 
10q) that will alter PTEN have been seen. PTEN also takes part to G1 cell cycle arrest 
and apoptosis in GBM. (Koul, 2008) 
Tumor suppressor gene retinoblastoma (RB, retinoblastoma) has central role as a cell 
cycle regulation taking part to G1 checkpoint. RB and its downstream pathway are also 
participating differentiation, proliferation, apoptosis, maintaining chromosomal stability 
and regulating cell cycle arrest. It can bind to various transcription factors inhibiting or 
promoting the transcription. RB also participates on control of enzymes that remodel 
chromatin structure and regulate expressions of target genes. (Burkhart & Sage, 2008) 
RB gene alterations in GBM include mutations or deletions of gene as well as methylation 
of promoters and alterations on regulators of RB pathway (Crespo et al., 2015).    
Tumor protein 53 (TP53, tumor protein 53) is a transcription factor that binds to DNA 
activating transcription or modulating other transcription proteins. It is affecting many 
cellular processes including cell cycle regulation, cell death, differentiation and cell re-
sponse to damages in DNA (Shangary & Wang, 2009). It can promote DNA repair during 
cellular stress or promote cell death if damage is impossible to repair. This way TP53 
prevents cells with damaged DNA from dividing inhibiting tumor formation and progres-
sion. (Crespo et al., 2015) Amplification and mutation of TP53 are seen in GBM as well 
as overexpression of its negative regulator MDM2 (E3 ubiquitin protein ligase) and some 
other alterations that will inhibit the activity of TP53. Some genetic alteration of 53 or a 
member of its downstream pathway has been detected by TCGA at 87 % of glioblastomas 
(TCGA Research Network, 2008).  
Cyclin dependent kinase inhibitor 2A (CDKN2A, cyclin dependent kinase inhibitor 2A) 
is a tumor suppressor gene that is frequently mutated in different cancers. CDKN2A en-
codes tumor suppressor protein p16 and takes part to cell cycle control in the RB pathway. 
(Harland, M. 2012) Homozygous deletion of CDKN2A is seen in approximately 50 % of 
glioblastomas. (TCGA Research Network, 2008). Loss of CDKN2A leads to increased 
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proliferation and disrupts the control mechanisms of apoptosis. It is mainly seen in higher 
grade (III-IV) gliomas and is suggested to be one reason for more aggressive tumor for-
mation. (Reiss et al., 2015) 
3.4 Molecularly different primary and secondary GBM 
Histologically primary and secondary GBMs are very similar but they have some genetic 
and molecular differences. Many genetic alterations can be found on both types of GBMs, 
but some are more common in one type than the others. Figure 3 summarizes some alter-
ations on both types of GBMs. Isocitrate dehydrogenase (IDH, isocitrate dehydrogenase) 
mutation is one of the main mutations separating primary and secondary GBMs since it 
is mainly present in secondary glioblastoma (Louis et al., 2016). IDH wild type GBMs 
are mostly exhibiting genetic and molecular changes that are known in primary glioblas-
toma. Gain of chromosome 7 and loss of chromosome 10 as well as EGFR amplification 
or mutation are commonly seen in primary GBM (Aldape et al., 2015). PTEN, that is also 
localized in 10q is frequently lost or mutated in primary GBM (Crespo et al., 2015). Other 
important characteristics for primary GBM are homozygous deletion of CDK2N2A and 
CDKN2B. (Marumoto & Saya 2012; Wilson et al. 2014) Figure 3 lists some mutations 
that are commonly seen in primary and secondary GBMs.  
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Figure 3.  IDH1/2 mutation is one of the most important mutation separating pri-
mary and secondary GBMs. Other commonly seen mutations in IDH wild type 
and IDH1/2 mutated GBMs are also shown. Modified from (Aldape et al., 2015)  
 
For IDH1/2 mutant glioblastoma, first alteration after IDH mutation is hypermethylation 
of CpG islands (G-CIMP). After that there seems to be two alternative pathways for sec-
ondary glioblastoma development. Subset of secondary GBMs harbor mutations of TP53 
and ATRX and other subset show co-deletion of 1p and 19q as well as TERT mutations. 
(Aldape et al., 2015) Other common alterations in secondary GBM are 19q loss (meaning 
the loss of chromosome 19) (Figure 3) and LOHs of 13q and 22q (Wilson et al. 2014; 
Crespo et al., 2015).  
3.5 Different subtypes based on molecular markers 
Different classification of GBM based on genetic and molecular changes has been sug-
gested (Crespo et al., 2012; Freije et al., 2004; Phillips et al., 2006). Studies have aimed 
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on finding alterations that could also provide knowledge of disease progression and clin-
ical outcome. Most comprehensive analysis on genetic alterations was collected by 
TCGA. They published mRNA data from 206 GBMs and sequencing data of over 600 
genes from 91 GBMs that showed alterations of tyrosine kinase receptor pathways on 88 
% of GBM, TP53 signaling pathway alterations on 87 % of GBM and alterations on RB 
pathway on 78 % of GBM. (TCGA Research Network, 2008)   
According to TCGA data GBMs were divided to four different subtypes based on their 
genetic alterations and changes in the copy numbers: classical, mesenchymal, proneu-
ronal and neural type. Classical subtype is characterized by some of the most common 
genetic alterations in GBM. EGRF amplification was seen in 95 % of classical subtype 
GBMs, 93 % showed chromosome 7 amplifications and deletions on chromosome 10 and 
95 % of samples harbored homozygous deletion at Ink4a/ARF locus. Mesenchymal sub-
type is identified with high expression on CHI3L1 and MET as well as NF1 mutation or 
deletion. Mesenchymal subtype seems to be expressing more Schwann cell markers and 
microglial markers than other subtypes. Proneural subtype harbors more alterations on 
PDGFRA as well as IDH1 and TP53 mutations. These are same markers that have been 
seen in secondary glioblastoma, and most of the secondary GBM are classified as pro-
neural subtype. Neural subtype expresses highly some neuronal markers like NEFL, 
GABRA1, SYT1 and SLC12A5. Neural subtype has closest expression pattern to normal 
tissue in the brain. These subtypes also seem to be evaluating clinical outcome and re-
sponse of GBM to treatment. (Verhaak et al., 2010)   
DNA methylation alterations are widely present in gliomas and glioma-CpG Island Meth-
ylator Phenotype (G-CIMP) has been characterized in subset of gliomas (Noushmehr et 
al., 2010). Ceccarelli et al. (2016) performed large genomic analysis of diffuse gliomas 
and suggested updating the subtyping of gliomas based on their IDH mutation status and 
G-CIMP profile. Many different classifications for subtyping gliomas has been suggested 
and their relevance has also been widely questioned. More research is still needed for 
clear understanding of molecular alterations defining gliomas.   
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4. FUNCTION OF FGFR AND ITS MUTATION 
Signaling pathways of fibroblast growth factor receptor (FGFR) have proven their im-
portance in proliferation, migration, angiogenesis and survival of cells. FGFR pathway 
can have supplemental effect on vascular endothelial growth factor (VEGF, vascular en-
dothelial growth factor) and platelet derived growth factor (PDGF, platelet derived 
growth factor) pathways. (Lieu et al. 2011) Aberrations of FGFR have also shown to act 
as initiating oncogenes in some cancers. Gene amplification, mutations, translocations 
leading to fusion genes, alternative splicing of FGFR and overexpression of fibroblast 
growth factor (FGF, fibroblast growth factor) have been observed in different cancers 
including breast-, lung-, gastric- and ovarian cancer and glioblastoma. (Dienstmann et al. 
2014) 
4.1 FGFR/FGF signaling pathway 
FGFRs include four transmembrane tyrosine kinase receptors that bind FGF glycopro-
teins. There is also fifth receptor called FGFRL1 (FGFRL1, Fibroblast growth factor 
receptor like one) that can also bind FGF, but it doesn’t have the tyrosine kinase domain 
and therefore participates to different cell functions (Dieci et al. 2013). FGFRs are formed 
of three different domains: extracellular-, transmembrane- and cytoplasmic domain. Lig-
and binding happens in the extracellular domain that consists of immunoglobulin parts 
(IgI, IgII, IgIII) and acidic box formed by eight acidic residues (Figure 4). IgII and IgIII 
are mainly responsible for ligand binding and IgI and acidic box produce auto-inhibitory 
functions of the receptor. Due to the alternative splicing IgIII can also take isoforms IgIIIb 
and IgIIIc that can bind different forms of ligands. Transmembrane- and cytoplasmic do-
mains are comprised of juxta-membrane- and split kinase domains and a tail of carboxy 
terminal. (Dienstmann et al. 2014) 
FGFs are signaling molecules and their family consist of 22 members that have similar 
molecular structure. They are divided to hormone-like FGFs and canonical FGFs (Dieci 
et al. 2013). They are mostly secreted out of the cells, but transportation of FGF-1 and 
FGF-2 is not yet understood. FGFs have interactions with heparin sulfate proteoglycans 
(HSPG, heparin sulfate proteoglycans) at the cell surface that control the binding of them 
to FGFR (Figure 4). (Lieu et al. 2011) FGFs take part in embryogenesis by taking part on 
regulation of cell migration and differentiation as well as proliferation. In developed tis-
sues FGF participates in the regulation of nervous system, tissue and wound repair and 
angiogenesis during tumor formation. (Eswarakumar, Lax, & Schlessinger, 2005)  
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Figure 4. Structure of FGFR and its downstream signaling pathways RAS/MAPK 
and PI3K. MAPK phosphatases 1 and 3 (MKP1, MPK3), FGFRL1, Spotry pro-
teins (SPRY) and similar expression to FGF (SEF) can work as a negative feed-
back for FGFR downstream signaling. (Image from article Dieci et al. 2013) 
Figure 4 represents activation of FGFR and its downstream signaling pathways. Once the 
FGFR is activated it phosphorylates FGFR substrate 2 (FRS2, fibroblast growth factor 
receptor substrate 2) and growth factor receptor-bound 2 (GRB2, growth factor receptor-
bound 2). Those activate Ras Sarcoma (RAS) G-protein that will send a signal to the 
nucleus with the help of mitogen-activated protein kinase (MAPK, mitogen activated pro-
tein kinase) pathway. Another signaling route activated by FGFR is phosphoinositide 3-
kinase (PI3K, phosphoinositide 3-kinase) pathway. Phospholipase C-y (PLC-y) and sig-
nal transducer and activator of transcription (STAT) can also be activated by FGFR with-
out the help of FRS2 (Ornitz & Itoh, 2015). They can start the cascade leading also to 
MAPK pathway. (Dieci et al. 2013) FRS2 also takes part to negative regulation of FGFR 
signaling therefore balancing translation of FGF signal. E3 Ubiquitin ligase protein Cbl 
can form complex with GRB2 bound to FRS2. This results in ubiquitination of both FGFR 
and FRS2 blocking the signaling of FGF. (Eswarakumar, Lax, & Schlessinger, 2005). 
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4.1.1 RAS/MAPK pathway (ERK) 
After autophosphorylation of FGFR, adaptor protein GRB2 binds to FRS2 and then links 
RAS/MAPK signaling pathway to FGFR with the help of guanine nucleotide releasing 
factor sons of sevenles (SOS, sons of sevenles) protein. GRB2 bind to FRS2 with its SH2 
domain and to SOS protein with SH3 domain. (Kouhara et al., 1997) SOS binds to RAS 
creating the activation of a protein kinase cascade that finally proceeds to the activation 
of MAP kinase. First RAS binds to a threonine/serine kinase RAF (RAF, rapidly accel-
erated fibrosarcoma), which then binds and phosphorylates mitogen activated protein ki-
nase (MEK, mitogen activated protein kinase kinase). Finally, MAPK is phosphorylated 
by MEK. When MEK binds to MAPK it exposes tyrosine residue that is not exposed in 
inactive form of MAPK. MEK phosphorylates that tyrosine and also threonine residue 
close by. These phosphorylated amino acids change the conformation of MAPK so that 
ATP (ATP, adenosine triphosphate) is not able to bind to catalytic site and specific bind-
ing sites for substrates are formed. (Lodish et al., 2000) 
MAPKs are serine/threonine kinases that convert extracellular signals to different cellular 
responses. There are several different MAPK pathways that together regulate metabolism, 
mitosis, motility, apoptosis, survival and differentiation. Extracellular signal regulated 
kinases 1 and 2 (ERK, extracellular signal regulated kinase), c-Jun amino N-terminal 
kinases 1,2 and 3 (JNK 1,2 and 3) p38 isoforms and ERK5 are categorized as conventional 
MAPKs. Unconventional MAPKs comprise of ERK 3, 4 and 7 and nemo like kinase 
(NLK). ERK1/2 are activated by cell surface growth factor receptors and it has an im-
portant role in regulation of proliferation. MAPK family members further activate MAPK 
activated protein kinases which is a family of 11 members. Activation of those will finally 
result in responses on proliferation, differentiation, stress and inflammation for example. 
(Cargnello & Roux, 2011)  
4.1.2 PI3K pathway  
Another important downstream signaling pathway of FGFR is PI3K pathway that is con-
trolling cells proliferation and survival of cells by blocking apoptosis. After phosphory-
lation of FGFR and FRS2 and GRB2 binding, GRB2 binds to PI3K with the help of GRB 
associated binding protein 1 (GAB1, GRB associated binding protein 1). (Ornitz & Itoh, 
2015) PI3Ks are lipid kinases and they participate for example to cell survival, prolifera-
tion and differentiation via different signaling molecules. PI3Ks generate phospholipids 
called phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3, phosphatidylinositol (3,4,5) 
- triphosphate ), which will then activate protein kinase B (AKT, protein kinase B). AKT 
is a serine/threonine kinase that is found in three different isoforms, AKT1, 2 and 3. AKT 
can then phosphorylate many different proteins like glycogen synthase kinase 3 (GSK3), 
the forkhead family of transcriptome factors (FOXOs) and mechanistic target of rapamy-
cin (mTOR, mechanistic target of rapamycin). These proteins can regulate processes like 
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protein synthesis, metabolism and survival. MTOR is strongly associated with cell pro-
liferation, since it is regulating availability of nutrients, energy and nutrient levels and 
mitogenic signals.  (Liu et al., 2009)  
PTEN, an important tumor suppressor gene that is mutated in many cancers including 
glioblastomas, is regulating PI3K pathway activity in normal cells. PTEN can work as a 
tyrosine phosphatase as well as lipid phosphatase in cells. It is capable of eliminating 3’ 
phosphate from PI(3,4,5)P3 changing it to PI(4,5)P2 and therefore antagonizing activa-
tion of AKT on PI3K pathway. AKT participates in regulation of tumor growth and an-
giogenesis as well as cell survival (Koul, 2008). Loss of tumor suppressor PTEN is lead-
ing to cancer through uncontrolled signaling of PI3K pathway. (Liu et al., 2009)  
4.2 FGFR3:TACC3 Fusion 
Fusion genes are hybrid genes of two genes that have rearranged and fused together. They 
are found in many cancer and can work as oncogenic drivers or produce oncogenic fusion 
proteins in cancers (Dienstmann et al., 2014). FGFR3 fusion with TACC3 (TACC3, 
transforming acidic coiled-coil containing protein 3) was first found in glioblastoma and 
later also in bladder cancer (Parker et al., 2013; Singh et al., 2012; Williams et al., 2013). 
Since then other FGFR fusions have been found also in lung, thyroid, oral and prostate 
cancers. (Parker et al., 2014)  
Fusion genes can be formed by intrachromosomal or interchromosomal rearrangements 
meaning that genes are originally located in same chromosome or different chromosomes. 
Tandem duplication and deletion are intrachromosomal fusion formation methods. Fusion 
of FGFR3 and TACC3 happens by intrachromosomal tandem duplication on 4p16.3 
which means that before the rearrangement TACC3 is located upstream of FGFR3 but 
after fusion their order is reversed (Figure 5). Deletion happens when part of the DNA 
between two genes is deleted. This way rearrangement of two fused genes stays same as 
it was before the fusion. Translocation is an interchromosomal mechanism that happens 
when double stranded DNA break occurs and strands are rearranged and joined together 
differently than before the break. (Parker et al., 2014) 
 
Figure 5. Formation of tandem duplication on FGFR3:TACC3 (Parker et al., 2013).  
Fusion happens primarily so that IIIc isoform of FGFR3 breaks at exon 18 fusing with 
smaller portion of TACC3 that can break at different exons. Different types of FGFR3 
fusions with TACC3 are shown in Figure 6. However, diversity between breakpoints in 
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different tumors has been shown and length changes on FGFR3 side have also been seen. 
Some fusion samples are shown to be formed so that breakpoint is situated downstream 
of FGFR3. Two genes are transcribed as so called read through transcripts and then 
through splicing terminal exon of FGFR3 is removed. This will lead to transcript of two 
genes fused together (Akiva et al., 2005).  FGFR3:TACC3 fusion leads to the loss of 
3’UTR of FGFR3. Usually in normal brain and in GBM without fusion expression of 
FGFR3 is low due to a negative control of miR-99a binding to the UTR region. miR-99a 
is regulating FGFR3 expression and this is why in GBMs with FGFR3:TACC3 fusion 
FGFR3 expression is enhanced. (Parker et al., 2013; Parker et al., 2014)  
 
Figure 6.  Different ways FGFR3 can fuse with TACC3 (Wu et al., 2013). 
Like discussed in chapter 2.3, in GBM genes PDGFRA, MET and EGFR are often am-
plified. However, it has been proven that FGFR3-TACC3 fusion is mutually exclusive 
for these amplifications as well as alterations of TP53. Furthermore, FGFR3:TACC3 fu-
sion seems to be expressed only in IDH wild type tumors (Di Stefano et al., 2015). These 
findings suggest FGFR3:TACC3 fusion might be initiating factor for GBM providing 
alternative pathway for tumor formation. In cellular level FGFR3:TACC3 fusion is pro-
moting proliferative capability and anchorage independent growth of the cells therefore 
accelerating tumor progression compared to wild type FGFR3. Fusion has also shown to 
promote cell transformation and to increase aneuploidy.  (Parker et al., 2013; Singh et al., 
2012)  
FGFR3:TACC3 fusion positive glioblastomas are more often found on women and they 
seem to be more aggressive than fusion negative tumors. FGFR3:TACC3 fusion can be 
detected from tumor samples with FGFR3 recognizing antibody. Immunohistochemical 
staining of FGFR3 in tumor samples have been heterogeneous, showing that not all the 
cells in fusion positive GBM tumors express FGFR3:TACC3 fusion but some of the cells 
are negative for this fusion. (Granberg et al., 2017)  
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5. TARGETING FGFR3:TACC3 FUSION WITH IN-
HIBITOR 
Expression of FGFR3 is low on normal brain cells. As discussed in chapter 3.2 loss of 
UTR in FGFR3:TACC3 fusion leads to higher expressions of FGFR3 in fusion positive 
cells suggesting that inhibition of FGFR3 might cause smaller neurological effects due to 
lower impact of inhibition on normal cells. Development of inhibitors that could cross the 
blood brain barrier is challenging and administration straight to the cerebral spinal fluid 
could be the more effective for brain tumor treatment. This way inhibitor could avoid 
contact with other organs with higher levels of FGFR3. (Parker et al., 2014)  
5.1 Anti FGFR drug for FGFR signaling inhibition 
Different drugs are being developed for inhibition of FGFR. Small molecule tyrosine ki-
nase inhibitors are already in clinical trials and commercially available. Monoclonal anti-
FGFR antibodies and drugs that can trap FGF are also being developed. Tyrosine kinase 
inhibitors are targeting FGFRs intracellular tyrosine kinases. There are reversible inhibi-
tors that occupy the ATP binding site of the tyrosine kinase and irreversible covalently 
binding inhibitors that bind to a cysteine residue of the tyrosine kinase (Katoh 2016). 
There are inhibitors available that are highly selective for FGFR but also those that are 
selective for also other tyrosine kinases like vascular endothelial growth factor receptor 
(VEGFR, vascular endothelial growth factor receptor) kinases. Multitarget inhibitors 
have shown better antitumor activities than selective inhibitors, but they have more VEGF 
related toxicity issues. Selective inhibitors have only FGFR related toxicity issues, which 
would make them a better candidate for combination treatments with other medicines. 
(Dieci et al. 2013) 
FGF-signaling takes part on tumor development in many ways. FGFs take part in para-
crine signaling, angiogenesis and immune evasion of tumor microenvironment. Studies 
have suggested that besides inhibiting effect on overexpression of FGFR in cancer cells, 
inhibitors could have effect on regulation of tumor microenvironment as well. Based on 
recent findings FGF signaling has also been suggested to be one reason for development 
of drug resistance in various cancers. Therefore, FGFR inhibitors are studied to block 
tumor progression in FGF altered tumors, to target angiogenesis in different types of can-
cers and to prevent resistance that cancer cells seem to acquire for targeted therapies. 
(Dieci et al. 2013; Katoh 2016) 
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5.2 Targeting FGFR3 with JNJ-inhibitor  
JNJ-42756493 is orally administrated pan-FGFR tyrosine kinase inhibitor. It targets all 
members of the FGFR family and has low activity on other kinases like VEGFR. It in-
hibits phosphorylation of tyrosine kinases of FGFR by targeting their intracellular ATP-
binding site. Its effective on concentrations at nanomolar level and it has a half-life of 50–
60 h. (Tabarnero et al., 2015) Orally administered JNJ-42756493 has high tissue distri-
bution to lung, kidney and liver tissues, but distribution to brain across blood-brain barrier 
is not well known. (Perera et al., 2014)  
JNJ-42756493 has been studied in vitro in FGFR signaling dependent engineered and 
tumor cell lines where it has shown inhibition of FGFR signaling and proliferation. Cells 
take inhibitor into lysosomal compartment rapidly and possibly due to its slow release 
from those compartments it inhibits FGF signaling for prolonged times. Furthermore, 
JNJ-42756493 has shown tumor inhibitory effects both in patient derived cells and in 
vitro cell line established FGFR signaling dependent xenograft models. It is shown to 
decrease phosphorylation of FGFR end ERK which could lead to observed antitumor ac-
tivity. (Perera et al., 2017; Tabernero et al., 2015)  
JNJ-42756493 is currently on clinical phase II safety evaluation studies. Phase I studies 
have shown no toxicities that are related to VEGFR, like proteinuria or hypertension. In 
high doses, it will cause FGFR related hyperphosphatemia, but with lower or intermitted 
doses toxicity has been manageable. It has also shown preliminary tumor inhibitory re-
sults in patients diagnosed with FGFR alterations in their solid tumors. (Tabernero et al., 
2015)  
Di Stefano et al. studied JNJ-42756493 inhibition in FGFR3:TACC3 cells in vivo and 
vitro showing that cells with FGFR3:TACC3 fusion were highly sensitive to inhibition in 
contrast to cells with inactivated fusion or empty vector. Antitumor results were also seen 
on xenograft model harboring FGFR3:TACC3 fusion. They evaluated effects of orally 
administrated JNJ-42756493 inhibitor on FGFR3:TACC3 with two patients harboring the 
fusion. Both patients showed clinical improvement after JNJ-42756493 treatment as well 
as tumor size reduction. Both patient showed some toxicity symptoms; hyperphos-
phatemia, asthenia, dry mouth, and nail changes for example. However, all the symptoms 
were mild and manageable. (Di Stefano et al., 2015)  
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6. INTRODUCTION TO PROTEIN DETECTION 
Western blotting is often used in cell and molecular biology for detecting specific proteins 
and their expression levels from cell samples containing mixture of different protein 
(Mahmood & Yang 2012). Other way to detect antibody depended proteins and their lo-
calization in cells samples is immunohistochemistry (Duraiyan et al. 2012). In this work, 
expression of FGFR3 and different downstream pathways of FGFR3:TACC3 fusion were 
evaluated using Western blotting method. Also, number of transfection positive cells was 
estimated using immunohistochemical staining methods. Principles of these methods are 
explained in this chapter.  
6.1 Western blotting method 
Western blotting is a method to separate and identify wanted proteins from complex mix-
tures of different proteins. First proteins are separated using SDS-PAGE (polyacrylamide 
gel electrophoresis, PAGE; sodium dodecyl sulfate, SDS), which is a protocol to separate 
different proteins according to their size, conformation and charge using electric field. 
Proteins are denatured with SDS before the run to make them negatively charged. Due to 
the negative charge, they will move towards the positive electrode. Smaller proteins move 
faster than larger proteins making separation by size possible. (Mahmood & Yang 2012) 
In electrophoretic transfer proteins are transferred from the gel to the membrane using 
electric voltage as a driving force. Membrane will work as a solid support for the protein 
bands during detection. During the transfer membrane is placed between the gel and a 
positive electrode so that the electric field will move proteins from the gel to the mem-
brane. Two different kind of membranes are available, nitrocellulose and PVDF (PVDF, 
polyvinylidene fluoride) membranes. Nitrocellulose membrane has high affinity for pro-
tein but it is more brittle than PVDF. PVDF membranes give better support for proteins 
but have higher background staining. (Mahmood & Yang 2012) 
Membrane needs to be blocked before detection to prevent nonspecific binding of anti-
bodies. Blocking will reduce background staining of the membrane. Blocking is usually 
done with 5 % BSA (BSA, bovine serum albumin) or nonfat milk. Detection of proteins 
of interest is done with protein specific primary antibodies and secondary label antibody 
with enzyme like HRP (HRP, horseradish peroxidase). Enzyme produces a signal that 
can be detected on a film. Protein bands can be evaluated and the thickness of the band 
relates to the amount of the protein in the sample. (Mahmood & Yang 2012) 
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6.2 Fast immunohistochemical staining 
Immunohistochemistry (IHC, immunohistochemistry) is a technique to detect antibody 
specific antigens from tissue or cell samples. IHC can be used for example to detect over-
expressed or tumor specific antigens in diagnosis of cancer. Tissue or cell samples are 
first fixed to preserve the cell and tissue structure and prevent the degradation (Alturki-
stani et al. 2016). Then tissue sections or cell samples are incubated in antigen specific 
primary antibody after which detection is done using label antibody linked with enzyme, 
fluorescent dye or some other detection molecule. Results can be visualized with light 
microscope or fluorescent microscope depending on used detection molecule. (Duraiyan 
et al. 2012) 
Fast immunohistochemical staining protocols have been developed where antibodies are 
incubated in higher temperatures for faster reactions. These methods can be used during 
operations to detect specific tumor markers for example. (Kämmerer et al., 2001; Richter 
et al., 1999) For this study, protocol used was designed for FGFR3 antibody at 41.5 °C.  
Staining in this study was done enzymatically using HRP enzyme and DAB (3,3 Dia-
minobenzidine) substrate. Enzyme linked to antibody is reacted with substrate to achieve 
color that can be visualized (Nakane & Pierce 1967). DAB is a chromogen typically used 
as a substrate for HRP enzymes. DAB creates dark brown staining that can be detected 
with light microscope. Hematoxylin is commonly used in histology as a counterstain for 
different stains like DAB and is bind to nuclei and nucleic acids of cells dying them blue. 
(Boster 2017) 
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7. INTRODUCTION FOR IN VITRO FUNCTIONAL 
TEST 
Cell culture is easy and cost-effective way to study cellular mechanisms of different tis-
sues and effects of different drugs on those mechanisms. In this study, different functional 
tests for cell lines were performed to assess differences between FGFR3:TACC3 fusion 
and FGFR3 overexpressed cell-lines as well as control cell lines. This chapter explains 
the basic principles behind those functional tests. 
7.1 Viability and proliferation 
There are several different methods to assess cell proliferation, viability and cytotoxicity. 
Most commonly used methods are created multi-well plate systems and can be measured 
with plate reader. Protease activity assays, tetrazolium reduction and reassuring reduction 
are the most common assays and are based on enzymatic or metabolic activity in the cells. 
In this study, we used tetrazolium reduction assay with MTT (MTT, 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide) to detect the number of viable cells. (Riss et 
al., 2004; Stockert et al., 2012)  
MTT is cell permeable and inside the cells NAD(P)H dependent oxidoreductase enzymes 
are converting MTT to a purple colored formazan product. Dead cells don’t have this 
ability therefore making it possible to evaluate only number of viable cells. Inside the 
cells formazan stays as an insoluble substance until it is solubilized to stabile color. For 
instance, acidified isopropanol, SDS, dimethyl sulfoxide (DMSO, dimethyl sulfoxide) and 
dimethylformamide can be used to solubilize formazan. Purple formazan product has an 
absorbance maximum around 570 nm which can be measured with plate reader. Absorb-
ance is dependent on the number of viable cells as well as their metabolic activity. Also, 
concentration of MTT and incubation time can have effect on the absorbance. (Riss et al., 
2004)  
There are some culturing conditions that may affect cells capability to reduce MTT to 
formazan. Changes in pH and loss of some nutrients on cells may reduce the ability as 
well as confluence of the cells. If cell growth becomes contact inhibited, cells may slow 
down their metabolism slowing down also the reduction of MTT. (Riss et al., 2004)  
7.2 Colony Forming  
Colony forming (or colonogenic) assay has been used over 50 years to determine differ-
ences between cell-lines or differently treated cells in their reproductive viability (Rafehi 
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et al., 2011). Assay is basically testing the number of cells in population capable to un-
dergo unlimited division, so it evaluates single cells ability to form a colony. In all cell 
population only a fraction of cells has the ability to form colonies. Colony needs to have 
at least 50 cells to be included. (Franken et al., 2006)  
Basically, cells are seeded as a single cell suspension to a plate where they will attach and 
start to divide. They can be treated differently to evaluate effect of radiation or cytotoxic 
agents for example. They are grown for 1–3 weeks after which formed colonies are 
stained and calculated. (Rafehi et al., 2011)  
7.3 Migration of the cells 
Migration is a cell mechanism that includes movement in any direction resulting in new 
position of the cell in tissues (Gotsulyak et al., 2014). Migration happens all the time, 
during embryonic development, wound healing and in our immune system for example. 
Migration plays also important role in cancer since migration of endothelium is a begin-
ning of blood vessel formation in tumor tissue. Furthermore, cancer metastases are ini-
tially formed by tumor cells migrating to circulation and from there to new tissues. (Hor-
witz & Webb, 2003)  
Wound healing assay is based on a scratch made on a confluent monolayer of cells. 
Scratch is imaged right after it is made and then after certain incubation time, when cells 
have started to migrate and fill the scratch. Assay measures and compares cells ability to 
migrate and fill the scratch. (Justus et al., 2014) 
7.4 Apoptosis and necrosis 
Apoptosis is a well-organized event in cells that leads to a morphological and biochemical 
changes and finally to cell death. Apoptosis is characterized by chromatin condensation, 
reduction in cell volume, nuclear fragmentation and membrane blebbing for instance 
(Atale et al., 2014). Apoptosis is essential for maintaining homeostasis in organisms as 
well as regulating some physiological processes. In normal cells PI3K pathway promotes 
cell growth and blocks apoptosis. Because in many cancers cell PI3K pathway is over 
activated it leads to inhibition of apoptosis and even higher proliferation of cancer cells. 
(Kalimuthu & Se-Kwon, 2013) 
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Figure 7.  Annexin V can bind to apoptotic cell that has phosphatidyl serine residues 
exposed to the outer leaflet of plasma membrane. In dead cells PM has already 
disrupted and PI can enter cell nucleus staining the cells. (Synentec, 2016) 
Annexin V – FITCH (fluorescein isothiocyanate) and PI (propidium iodide) double stain-
ing is a way to detect apoptotic cells from necrotic and viable cells by the differences in 
the permeability and integrity of their cell membrane (Rieger et al., 2011). Method of 
Annexin V – FITCH and PI binding on viable, apoptotic and necrotic cells are shown in 
figure 7. Loss of phospholipid membrane (PM, phospholipid membrane) asymmetry is 
one of the early apoptotic events in cells. Phosphatidyl serine residues are flipped to the 
outer leaflet of the PM and annexin V can interact with those residues in the presence of 
Ca2+. In viable cells PM is intact and phospahtidyl serine located in the inner leaflet of 
PM therefore making it impossible for annexin V to bind. PI is red fluorescent dye that 
binds to DNA. It can only stain dead cells that have already disrupted PM so it can pene-
trate PM and transport to nucleus. Therefore, cells in apoptosis are positive for Annexin 
V staining, but negative for PI staining. Necrotic cells on the other hand are positive for 
both stains. Viable cells with intact PM are negative for Annexin V and PI. (Atale et al., 
2014)  
7.5 SNB19 Glioblastoma cell line  
SNB19 glioblastoma cell line was used for all the experiments in this study. SNB19 cell 
line was derived in 1980 from a 47-year-old male patient from surgically removed tissue 
sample of his left parieto-occipital glioblastoma multiforme tumor.  This cell line has 
maintained its transformation and differentiation capabilities as well as tumorigenesis 
even after 13 years of culture and over 200 passages. SNB19 cell line is adherent mor-
phologically fibroblast like cell line that proliferates fast, has ability for anchorage inde-
pendent growth and expresses high level of proteins. These cells have doubling time 
around 52 h, saturation density 7,8x104 cells/cm2 and their colony forming efficiency in 
soft agar is 41,5 % (Gross et al., 1988). SNB19 cells can develop in vivo tumors that 
resemble the original tumor even after a long culture times and show all the same prop-
erties as GBM shows in vivo. (Welch et al., 1995)  
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8. MATERIALS AND METHODS  
Glioblastoma SNB19 cell line had been transfected with vector containing either 
FGFR3:TACC3 fusion, FGFR3 or empty vector. Cells transfected with empty vector 
were used as control cells. Transfection had been done with the antibiotic resistant se-
lectable marker. Then cells had been cultured with selection antibiotic (Geneticin, Gibco), 
so that unsuccessfully transfected or transiently transfected cells would die and stably 
transfected cells would survive. Stably transfected clones had been selected as colonies 
and transferred as single cells to be cultured in selection media to ensure their resistance 
to antibiotic. This stable transfection method includes transfected DNA to the cells ge-
nome making the transfection long lasting. Transfection efficiency was evaluated with 
Western blotting and immunohistochemically. Growth, survival, migration and invasion 
capabilities of the chosen cells were studied with functional testing and response of the 
cells to FGFR inhibitor and FGF stimulation was assessed. 
8.1 Cell-line analysis using Western blot method 
Western blotting protocol was used to analyze SNB19 cell-lines of which five had been 
transfected with FGFR3 containing vector, five with FGFR3:TACC3 containing vector, 
and eight controls that had been transfected with empty vector.  
8.1.1 SDS-PAGE protocol 
First four gels for SDS-PAGE were prepared. 10 % and 8 % gels were used for the run-
ning gel and 5 % gel for the stacking gel. Ingredients and their volumes are represented 
in table 2.  
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Table 2. Ingredients and volumes used to prepare SDS-page gels 
Ingredient 
Running gel 
10% 
Running gel 
8% 
Stacking gel 
5% 
Acrylamide (30 %) / 0,8 % Bis-Acryla-
mide (ml) 
10 8 2,5 
Water (ml) 12,2 14,2 10,3 
1,5 M Tris-HCl, pH 8.8 + 0,4 % SDS 
(ml) 
7,5 7,5 - 
0,5 M Tris-HCl, pH 6.8 + 0,4 % SDS 
(ml) 
- - 1,9 
10 % APS (µl) 300 300 160 
TEMED (µl) 20 20 10 
 
First 10 % running gel layers, next 8 % gel layers and finally at the top 5 % stacking gel 
layers were casted. Into the stacking gel layer combs were pushed to make the wells for 
samples. Between every layer, gels were allowed to solidify for 45 min. Gels were left to 
set on the fridge overnight.  
Next day samples were diluted to H20 so that each sample had the concentration of 1 
mg/ml. Protein levels had been measured prior to these Western experiments using DC 
Protein Assay –kit (Cat#5000112, Biorad). 4xsamplebuffer was added to the samples and 
then they were boiled in 91 ºC for 5–10 min. Gels were placed to a chamber where 1 x 
SDS Running buffer was added. Samples were pipetted to the wells in a gel. Gels were 
run first for 10–15 min at 100 V and when the samples had reached the boarder of running 
gel at 120 V approximately for 2 h.  
8.1.2 Western blot protocol 
Proteins were transferred from gels to membrane using process called electroblotting, 
which is explained in chapter 6.1. Voltage used for electroblotting was 100 V for 1 h 
30min and buffer was 1 x transfer buffer in 20 % methanol. Then membranes were cut in 
three pieces so different pieces could be processed with right antibodies and different 
proteins could be detected. Membranes were washed ones. All the washes in the protocol 
were done using TBST (Tris-buffered saline + 0.1 % Tween 20). Membranes were 
blocked using 5 % non-fat milk in TBST solution for 1h and then washed again. Primary 
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antibodies (FGFR3, pAKT and pERK) were diluted to blocking buffer and added to sam-
ples and incubated overnight +4 ºC. Then membranes were washed three times 5–10 min 
and incubated in secondary antibodies for 1 h in RT (room temperature, RT). Antibodies 
and their dilution ratios for different proteins are listed in the table 3.  
Table 3. Antibodies and their dilution ratios used to detect sizes of different proteins  
Protein 
detected 
Primary antibody 
Dilu-
tion ra-
tio 
Secondary antibody 
Dilu-
tion ra-
tio 
FGFR3 
(B-9) SC-13121 Lot 
#B0414 Mouse monoclo-
nal IgG, Santa Cruz Bio-
technology 
1:300 
Polyclonal Rabbit anti-
mouse Immunoglobu-
lins/HRP Lot 00055754, 
Dako 
1:1000 
pAKT 
(D9E) XP Rabbit mAb 
Lot. 16 #4060L, Cell Sig-
naling Technology 
1:1000 
Polyclonal Swine anti-
rabbit Immunoglobu-
lins/HRP, Dako 
1:2000 
AKT 
AKT Rabbit AB Lot 27 
9272S, Cell Signaling 
Technology 
1:1000 
Polyclonal Swine anti-
Rabbit Immunoglobu-
lins /HRP Lot00093964, 
Dako 
1:2000 
pERK 
P-p44/42 MAPK 
(T202/Y204) XP(R) Rab-
bit mAb Lot 12 4370S, 
Cell Signaling Technol-
ogy 
1:2000 
Polyclonal Swine anti-
rabbit Immunoglobu-
lins/HRP, Dako 
1:2000 
ERK 
P44/42 MAPK (ERK1/2) 
137F5 Rabbit mAb Lot 
14, Cell Signaling Tech-
nology 
1:500 
Polyclonal Swine anti-
Rabbit immunoglobu-
lins/HRP, Dako 
1:2000 
GAPDH 
GAPDH (H-18) SC-
20357 Lot#B2814 Goat 
polyclonal IgG, Santa 
Cruz Biotechnology 
1:500 
Polyclonal Rabbit anti-
Goat Immuno-
glonulins/HRP Lot 
00035737, Dako 
1:1000 
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After secondary antibodies membranes were washed again three times. For the detection 
ESL solution was prepared (50 % Western blotting luminol reagent A and 50 % Western 
blotting luminol reagent B, Immuno Cruz) and pipetted 1ml on top of every membrane. 
Then membranes were moved to Kodak Biomax Cassette and filmed in the dark room 
using AGFA CP1000 film processor.  
After first detection, total amount of AKT and ERK were detected from membranes using 
AKT and ERK specific antibodies (Table 3). Primary antibodies were incubated on mem-
branes again overnight in +4 ºC and secondary antibodies in RT for 1 h. Washing steps 
and detection of proteins were repeated same way as earlier.  
Lastly GAPDH that is used as a loading control in this experiment was detected from the 
membrane. Antibodies are again listed in table 3, and incubations, washes and detection 
were done similarly.  
8.2 Staining of stable cell lines 
Slides were made of each cell sample and were stained with Fast IHC (immunohisto-
chemical) staining protocol. First slides were fixed for 2 min in acetone at -20 ºC. Staining 
was done with protocol presented in table 4.  
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Table 4. Fast IHC Staining protocol for SNB19 cell lines. All the steps were done on JL-
stainer heat plate at 41.5 ºC. 
Step Reagent Time 
Wash TBS (Tris-buffered saline) 10 s 
Peroxidase block-
ing 
H2O2 (Hydrogen Peroxide Solu-
tion 3 %, Sigma Aldrich 88597) 
1 min 
Wash 
0,5 % TBST (0,5 % Tween 20 in 
Tris-buffered saline) 
10 s 
Primary antibody 
FGFR3 (sc-13121, SCBT) 1:100 
diluted in Dako antibody diluent 
5 min 
Wash 0,5 % TBST 10 s 
Secondary Anti-
body 
Immunodiagnostics N-Histofine 
Simple Stain MAX PO (MULTI) 
3 min 
Wash 0,5 % TBST 10 s 
Staining 
DAB (ImmPACT DAB Peroxi-
dase Substrate Kit, Vector) 1:50 
1,5 min 
Wash H2O 10 s 
Staining hematoxylin 10 s 
Wash 0,5 % TBST 10 s 
Wash H20 2 x 10 s 
 
After staining, slides were dehydrated (2 min in 70 % ethanol, 2 min in 94 % ethanol, 2 
min in absolute ethanol and 2 x 10 min in xylene) and mounted. Slides were imaged with 
Olympus BX41 light microscope and MShot digital imaging system. Cell samples were 
stained with same procedure again after 5 weeks of culture to assess whether the expres-
sion is stable in the cells. Results of that staining are presented in Appendix 1.   
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8.3 Functional tests of stabile cell lines 
Based on Western blotting and Fast IHC staining four cell lines were selected for further 
studies (FGFR3:TACC3, FGFR3 and two control cell-lines). Proliferation, colony for-
mation, migration and invasion of these cells were evaluated. Response of inhibitor on 
these features were also assessed. Cells were cultured in DMEM F-12 Nutrient mixture 
(Gibco) containing 10 % fetal bovine serum (FBS, fetal bovine serum, Sigma Alldrich), 
1 % glutamax (Gibco, 35050-061) and 900 µg/ml Geneticin (Gibco) if not otherwise 
mentioned. 
8.3.1 Proliferation studies with MTT viability assay 
Cells were plated on 96-well plates 300 cells/plate. Cells were calculated using Bürker 
chamber. Plates were incubated overnight. Cell proliferation was studied during seven 
days of culture, so that the viability of cells was measured every other day starting from 
the day after cells were plated. Effects of JNJ-42165279 inhibitor on proliferation was 
studied so that 10 nM, 200 nM or 1 µM inhibitor media was added to the cells the day 
after they were plated. For control cells, fresh media containing 0,01 % DMSO (Dimethyl 
Sulfoxide, Sigma) was added. Cells were cultured 7 days and media was changed once 
after 4 days.    
Measurements were done with MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazo-
lium bromide). MTT was diluted to cell media (1:10) and added to the cells and cells were 
incubated for 3 h. Cells were centrifuged for 5 min with 300*g in RT. MTT reagent was 
removed and 150 µl DMSO was pipetted to the wells. Plates were then shaken for 5–10 
min and absorbances were measured with Perkin Elmer UV/VIS Envision. Both experi-
ments were done four times to verify the results.  
8.3.2 Colony forming  
Cells were plated on 6-well plates 300 cells/well. 1 µM or 200 nM inhibitor media (JNJ-
42165279) was added on half of the wells. Other half were used as controls for inhibition 
and were treated with normal media containing 0,01 % of DMSO. Cells were incubated 
for 10 days and both medias were changed once after five days of incubation. Cells were 
stained with 0,5 % Crystal Violet in 20 % methanol. Cells were imaged and colonies were 
counted with ImageJ. Colony formation assay was repeated four times to ensure the re-
sults.  
8.3.3 Migration 
Cells were plated on 12-well plates so that the cell layer was confluent the next day 
(180 000 cell/well for FGFR3:TACC3, FGFR3 and control 5 and 160 000 cells/well for 
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control 2). Wound was made to the cell layer with 1 ml pipet tip. Media was changed 6h 
before wound making so that half of the wells had 1 µM inhibitor media (JNJ-42165279) 
and other half had control media containing 0,01 % DMSO. Wounds were imaged right 
after at 0 h and again after 21 h of incubation with Zeiss Axio Vert A1 microscope. Images 
were analyzed using ImageJ wound healing tool to calculate the area of wound. Wound 
healing assay was repeated four times.  
8.3.4 Survival assay 
Survival of cells was studied with Annexin V – FITCH kit (Milteney Biotec, 130-092-
052). Cells were plated 100 000 cells/well to 6-well plate and incubated over night at 37 
ºC. 1 µM JNJ-42165279 media or 0,01 % DMSO as a control was changed to the cells. 
Cells were left to incubate for 24 h and collected from wells with 0,05 % EDTA. Cells 
from every two wells were combined as one sample.  
Staining of the cells was done according to manufacturer’s instructions (Milteney Biotec, 
Annexin V – FITCH kit). Shortly, cells were first washed with 1 x binding buffer and 
centrifuged at 300*g for 10 min. Supernatant was aspirated and cells were suspended at 
100 µl of binding buffer. Annexin V – FITCH was mixed to the cell suspension and so-
lution was incubated 15 min in the dark at RT. Cells were then washed again with binding 
buffer and centrifuged for 10 min at 300*g. Supernatant was removed and cells were 
resuspended at 500 µl of binding buffer. PI stain was added to samples just before ana-
lyzing the samples with BD Accuri C6 flow cytometry. One negative sample without the 
stains was made for each cell sample. Also, one sample with only Annexin V – FITCH 
and one sample with only PI stain was made to balance the colors for analysis. Survival 
assay was done twice, first without inhibition and then with inhibition and control. Sur-
vival assay was repeated twice, first without inhibition and then with inhibition treated 
samples.  
8.4 FGF and inhibitor response of fusion cells 
Cells’ response to JNJ-42165279 inhibitor and FGF (Fibroblast growth factor) stimula-
tion on protein level was studied with FGFR3:TACC3, FGFR3 and control cell line. Pro-
tein samples were extracted from cell lines that were incubated in presence of the inhibitor 
or the growth factor. Differences in protein levels was evaluated with Western blotting.  
8.4.1 Cell response to FGF stimulation 
Cells were plated 10 cm plates 200 000 cells/plate. They were incubated overnight and 
starved for 48 h (culture without any growth factors in DMEM F-12). DMEM-F12 con-
taining 0,85 µg/ml FGF (Human FGF-basic, Cat# 100-18B, Peprotech) was added to 
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cells. Protein samples were collected 30 min, 2 h and 24 h after addition of FGF. Also 
control samples, where no FGF was added were collected. 
8.4.2 Cell response to JNJ-42165279 inhibitor  
Cells were plated 10 cm plates 150 000 cells/plate. They were incubated 48 h. Media 
containing 1 µM JNJ-42165279 was added on inhibited cells and for control cells normal 
media was changed. Protein samples for inhibited and control cells were collected 30 min, 
2 h, and 24 h after media change.  
8.4.3 Protein extraction and detection  
Protein samples were collected to RIPA buffer containing 1x protein phosphatase. Sam-
ples were sonicated for 7 min (30 s on/off) and centrifuged 2 min at 10 000*g. Protein 
concentrations of samples were measured with DC Protein Assay –kit (Cat# 5000112, 
Biorad) according to manufacturer’s protocol. Briefly, samples and BSA protein stand-
ards were pipetted to 96-well plate 5 µl/well. 20 µl reagent S was added to every ml of 
reagent A. 25 µl of mixture was pipetted to the wells. Then 200 µl of reagent B was 
pipetted to the wells. Absorbances were measured with Perkin Elmer UV/VIS Envision. 
Sample concentrations were evaluated in relation to the concentrations of BSA standards. 
Proteins were detected with Western blotting like was done in chapter 4.1. Blocking the 
nonspecific bonding of antibodies was done with 2,5 % milk + 2,5 % BSA mixture for 
phosphorylated FRFR membrane and with 5 % milk for other proteins. Phosphorylated 
FGFR was detected from membranes to evaluate the effects of inhibition and stimulation 
on phosphorylation. Phosphorylated STAT3 and total amount of STAT3 were detected 
to see the effects of inhibition and stimulation on JAKK/STAT downstream pathway. 
Antibodies used to detect these proteins are listed in table 5.  
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Table 5. Antibodies and their dilution ratios used to detect phosphorylated FGFR and 
STAT3 and total amount of STAT3.  
Protein 
detected 
Primary antibody 
Dilu-
tion ra-
tio 
Secondary antibody 
Dilu-
tion ra-
tio 
pFGFR3 
pFGF receptor 
(Y653/Y654) (55H2) 
Mouse mAb, Cell Signal-
ing Technology 
1:500 
Polyclonal Rabbit 
anti-mouse Immuno-
globulins/HRP Lot 
00055754, Dako 
1:1000 
pSTAT3 
P-STAT3 (Y705) (D3A7) 
XP(R) Rabbit mAB 
#9145S, Cell Signaling 
Technology 
1:2000 
Polyclonal Swine anti-
rabbit Immunoglobu-
lins/HRP, Dako 
1:2000 
STAT3 
STAT3 (124H6) Mouse 
mAb #9139, Cell Signal-
ing Technology 
1:1000 
Polyclonal Rabbit 
anti-mouse Immuno-
globulins/HRP Lot 
00055754, Dako 
1:1000 
 
Furthermore, total amount of FGFR3 and other downstream signaling pathways related 
to FGFR were evaluated with detection of phosphorylated ERK and AKT. Total amounts 
of ERK and AKT were also detected. As a loading control for the experiment GAPDH 
was detected. Antibodies used for FGFR3, pAKT, AKT, pERK, ERK and GAPDH de-
tection were same as in chapter 4.1 and are listed in table 3.  
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9. RESULTS 
Glioblastoma cell line (SNB19) was stably transfected with a vector containing 
FGFR3:TACC3 fusion, FGFR3 or an empty vector. Purpose was to evaluate differences 
between cell models expressing FGFR3:TACC3 fusion and normal FGFR3. Cells with 
empty vector were used as a control.   
9.1 Selection of cell lines with high proportion of FGFR3 posi-
tive cells  
Five cells lines with FGFR3:TACC3 transfection, five cell lines with FGFR3 transfection 
and eight control cell-lines with empty vector were analyzed first using Western blotting. 
Proteins detected from membranes were FGFR3, AKT and ERK. Also, phosphorylation 
levels of proteins ERK and AKT were evaluated. As a loading control for this experiment 
levels of GAPDH protein were detected. Results are shown in figure 8.  
 
 
Figure 8. Image panel shows detection of FGFR3, AKT and ERK proteins in all the 
samples. Also amount of phosphorylated ERK and AKT are shown. GAPDH is 
shown as a loading control.  
Samples FT4 and F2a were discarded since FGFR3 expression was low or nonexistent in 
these samples. Rest of the samples were then analyzed with fast IHC staining. Cells ex-
pressing FGFR3 stained brown and cells that did not express FGFR3 stained blue. Figure 
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9 shows staining of control cells and figure 10 staining of fusion transfected cells and 
FGFR3 transfected cells. 
 
Figure 9. Control cells stained with fast IHC staining for FGFR3. 
 
 
Figure 10. Upper row shows the FGFR3 transfected cells and lower row 
FGFR3:TACC3 transfected cells stained with fast IHC staining for FGFR3. 
Stained slides were analyzed and number of FGFR3 positive cells was evaluated with 
light microscope Olympus BX41 light microscope. Percentages of FGFR3 positive cells 
in samples is shown in figure 11.  
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Figure 11.  Percentages of cells expressing FGFR3 in samples determined by 
immunohistochemical staining. 
Samples F6 and FT3 were selected for further studies, since these samples had over 70 % 
of FGFR3-staining positive cells. Percentage of FGFR3 positive cells in sample F2 was 
little under 50 % and in other cell lines under 30 %. All the other samples were discarded 
from the studies because the results would have not been reliable with them. Cells were 
stably transfected and clones were selected with selection antibiotic. This should provide 
cell lines with high expression of wanted protein. However, we noticed that during long 
time culture, over-expression of FGFR3 and FGFR3:TACC3 is lost in the cells. Appendix 
1 shows images of cells cultured for 5 weeks and stained with IHC staining. Also per-
centages of FGFR3 positive cells were calculated and especially FGFR3:TACC3 express-
ing line had significantly lower amount of FGFR3 positive cells after 5 weeks of culture 
than they had after couple days of culture. Stable transfection and selection takes long 
culturing times and this could be the one reason why expression of FGFR is lower on 
some cell lines.  
9.2 Proliferation capability of cells 
Proliferation of cells was assessed using MTT-viability assay. Measurements were done 
every other day starting on first day after plating and ending on seventh day from plating. 
Absorbances were measured with Perkin Elmer UV/VIS Envision. Figure 12 shows rel-
ative absorbances in proportion to first day absorbances. Values in all of the experiments 
are mean values of parallel samples and their standard deviations are also shown in fig-
ures.  
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Figure 12. Proliferation of FGFR3:TACC3, FGFR3 and control cells meas-
ured with MTT-viability assay. Absorbance values are mean values of parallel 
samples. Standard deviations of samples are also shown. Significant differences 
between cell lines are marked (two-way ANOVA, ***P<0,001. 
 
FGFR3:TACC3 cells were proliferating fastest and FGFR3 cells proliferate slower than 
control cell lines. There is a significant difference seen between two control cell lines as 
well. Effects of FGFR inhibition with JNJ-42165279 inhibitor on cell proliferation was 
also assessed. Cells were cultured 7 days after which viability of the cells was measured 
with MTT-assay. Figure 13 shows relative absorbance of parallel samples for inhibited 
and non-inhibited cells.  
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Figure 13. Proliferation of FGFR3:TACC3, FGFR3 and control cells without 
inhibitor and with different concentrations of inhibitor (10nM, 200nM, 
1000nM). Absorbance values are mean values of parallel samples. Standard de-
viations of samples are also shown. Significant differences are shown (two-way 
ANOVA, *P<0,05, **P<0,005, ***P< 0,001) 
Inhibitor has significant effect on FGFR3:TACC3 proliferation on all concentrations. For 
control cells, effect of inhibitor on proliferation is seen with 200 nM inhibitor concentra-
tion. However, effect of inhibition seen on control cells is lower than effect seen on fusion 
positive cells. For FGFR3 cells, no significant effect of inhibition to proliferation is seen.  
9.3 Colony formation of cells  
Ability of single cell to form colony was studied with colony formation assay. Figure 14 
shows panel of images with one example well containing each cell-types in different con-
centrations of JNJ-42165279 inhibitor and in control media. 
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Figure 14. Colonies formed by FGFR3:TACC3, FGFR3 and control cells with 
and without inhibitor.  
Colonies were calculated with ImageJ and figure 15 shows the mean value of number of 
colonies for FGFR3:TACC3 and FGFR3 expressing cells as well as control cells with 
1000nM and 200nM JNJ-42165279 inhibitor and with control media.  
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Figure 15. Number of colonies formed by different cell types (FGFR3:TACC3, 
FGFR3 or control) in control media and with 200nM and 1000nM JNJ-
42165279 inhibitor. Values are means of parallel samples. Standard deviations 
of samples are also shown. Significant differences are shown (two-way ANOVA, 
*P<0,05). 
There were no significant differences between different inhibitor concentration treated 
cells and control cells. FGFR3 expressing cells have lower colony formation capability 
than other of cells, but no significant differences were seen between fusion and control 
cells.  
9.4 Migration 
Cell migration was studied with wound healing assay. Cells were imaged right after the 
wound was made and again after 21h incubation in 37 °C. Images of cells with 1000nM 
JNJ-42165279 inhibitor and with control media are collected to figure 16.  
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Figure 16. Images of different cells (FGFR3:TACC3, FGFR3 and controls 2 
and 5) with and without inhibitor right after wound was made and after 21h incu-
bation (5x). Inhibitor treated cells are marked green and with control media 
treated cells blue.  
Images were analyzed using ImageJ wound healing tool. Percentage of area loss was cal-
culated and mean values of those percentages are presented in figure 17.   
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Figure 17. Percentage of wound healing meaning the wound area loss after 
21h incubation with FGFR3:TACC3, FGFR3 and control cells. Values are 
means of parallel samples. Standard deviations of samples are also shown.  No 
significant differences were seen (two-way ANOVA) 
There were no significant differences between migration of different cell lines. For fusion 
positive cells, some decreased effect on inhibition to the migration was seen but it was 
not statistically significant. Same effect was seen in control 2 cell line.  For FGFR3 and 
control 5, inhibition showed no decrease of migration.  
9.5 Survival of the cells  
Survival of cells was studied with Annexin V FITCH and PI staining and the samples 
were analyzed with BD Accuri Flow cytometer. Cells were divided to viable, apoptotic 
and necrotic cells according to the staining and percentages of each group is shown in the 
figure 18. 
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Figure 18. Percentages of viable, apoptotic, early necrotic and late necrotic 
cells in samples treated with 1000nM inhibition media or control media.  
Percentage of viable cells is lower with FGFR3 overexpressed cells than fusion or control 
cells. Percentage of early necrotic cells is on the other hand higher with FGFR3 cells. 
Percentage of apoptotic cells is similar on FGFR3 overexpressed cells and 
FGFR3:TACC3 overexpressed cells, but differs from percentage of apoptotic cells in both 
controls. All the control cell samples seem to have higher percentage of late necrotic cells 
than fusion or FGFR3.  
Inhibition treatment seem to be slightly lowering percentage of viable cells in FGFR3 and 
control 2 cells, however change is small so might not be significant. Furthermore, per-
centage of early necrotic cells is higher on those same samples as well as for control 5, 
suggesting that inhibition is decreasing survival by inducing necrosis on some FGFR3 
and both control samples. Percentage of viable cells is increased and apoptotic cells de-
creased in FGFR3:TACC3 fusion cells with inhibition, suggesting that inhibition would 
prolong survival of fusion positive cells. Survival assay was done twice, but only once 
with inhibitor treated samples, so some inhibitor effects on cell survival can be normal 
variation in the cell behavior. 
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9.6 Cell response to FGF stimulation 
Growth factor stimulation of different cell lines was assessed on protein level with West-
ern blotting, where expressions and phosphorylation levels of FGFR3 related downstream 
proteins were detected. For FGF stimulation experiment cells were first starved for 48h 
without any growth factors and then stimulated with FGF. Figure 19A shows effects of 
starvation at 0h samples and FGF stimulation on cells and their downstream proteins after 
30min, 2h and 24h of FGF addition. Intensities of bands were calculated with Image J 
and figure 19B shows bar plots of intensities of different proteins compared to GAPDH 
control.   
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Figure 19. Expressions of proteins from samples that were first starved (0h 
sample) and then stimulated different times (30min, 2h and 24h) with FGF(A). 
Band intensities as a percent of GAPDH control and relation of phosphorylated 
form to un-phosphorylated form are shown in (B).  
 
 K2         K2         K2        K2         FT         FT         FT         FT 
 0h       30min    2h       24h        0h      30min    2h       24h 
K5        K5         K5        K5         F6         F6           F6         F6 
0h     30min     2h       24h        0h      30min       2h        24h 
pFGFR 
FGFR3 
pAKT 
AKT 
pERK 
ERK 
pSTAT3 
STAT3 
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In FGFR3 and FGFR3:TACC3 cells, phosphorylation of FGFR goes up when cells are 
stimulated with FGF-2. After 24h stimulation phosphorylation will go down even lower 
than in starved samples. Effect is seen more clearly in FGFR3:TACC3 cells. FGFR3 cells 
have overall stronger phosphorylation expression than fusion cells. Some phosphoryla-
tion is seen also in control number 2. Blot showing relation of pFGFR and FGFR3 is not 
relevant for control samples since they have so low expression of FGFR3. Minos phos-
phorylation seen in controls could be caused by some other FGF receptor. Intensities of 
phosphorylated FGFR calculated with Image J include both glycosylated and non-glyco-
sylated form of FGFR.  
Some activation patterns for FGF stimulation can be seen for downstream signaling path-
ways as well. Phosphorylation of AKT goes down in FGFR3:TACC3 cells and up in 
FGFR3 cells when they are stimulated. Phosphorylation of ERK has similar pattern in 
FGFR3:TACC3 cells and control 2 cells; when stimulated, phosphorylation increases and 
returns back down after 24h. Control 2 has an air bubble at 30 min time point in total 
expression of ERK, which will lead to a lowered intensity of ERK in analysis. This then 
leads to increased intensity of pERK/ERK, so true effect seen on control 2 is lower than 
effect seen on plot. Phosphorylation of ERK is overall higher on FGFR3 wild type cells 
than other cells. Phosphorylation of ERK increases in FGFR3 cells after stimulation and 
stays up after 24h of stimulation. Control 5 does not have any significant changes in ERK 
phosphorylation. STAT3 phosphorylation goes down when FGFR3:TACC3, FGFR3 and 
control 2 cells are stimulated with FGF and returns back up after 2 h incubation. In control 
5 cells total STAT3 expression is really low, so its phosphorylation pattern difficult to 
determine. However, it seems that STAT3 phosphorylation also decreases when stimu-
lated.    
9.7 Cell response to inhibition 
Cells response to inhibition was studied with 30min, 2h and 24h inhibitor treatment with 
JNJ-42165279 inhibitor and compared to control cells treated with normal media. Phos-
phorylate FGFR and downstream protein AKT, and ERK and their phosphorylated forms 
were detected. GAPDH was used as a loading control. Figure 20A shows expression of 
these proteins detected with Western blotting. Intensities of bands were calculated with 
Image J and figure 20B shows bar plots of intensities of different proteins compared to 
GAPDH control.   
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Figure 20. Proteins from inhibitor treated and control samples after 30min, 2h 
and 24h treatment (A). Band intensities as a percent of GAPDH control and re-
lation of phosphorylated form to un-phosphorylated form are shown in (B).  
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Inhibition of FGFR in fusion and FGFR3 overexpressed cell lines seem to lower phos-
phorylation of FGFR, since all JNJ-42165279 treated FGFR3:TACC3 and FGFR3 treated 
cell lines have lowered FGFR phosphorylation expression compared to same time point 
control treated cells.  
Inhibition of cells does not seem to have clear effect on downstream signaling. AKT 
phosphorylation has decreased expression at 24h time point for control treated versus 
inhibited cells on FGFR3:TACC3, FGFR3 and control 2 cell lines. Overall phosphoryla-
tion of AKT is slightly decreasing during time. Furthermore, phosphorylation of ERK 
seem to lower as time passes on all cell lines and it is on its lowest at 24h time point in 
both control treated and inhibited cells. Slight decreasing effect of inhibition can be seen 
on pERK/ERK on FGFR3:TACC3 cells but not on other cells. STAT3 phosphorylation 
on the other hand seem to be increasing during the incubation, as it is on its highest at 24h 
time point. However, looks like total amount of STAT3 is also increasing in the cells 
during that 24h incubation.  
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10. DISCUSSION 
In this study, FGFR3:TACC3 expressed cell line was compared to FGFR3 expressing and 
control cells lines. Stably transfected overexpression cell lines were used to compare 
those differences. Previous studies have shown FGFR3:TACC3 fusion to increase prolif-
eration and anchorage independent growth of the cells (Parker et al., 2013). Aim was to 
see if our cell models behave similarly and could be used as a model for FGFR3:TACC3 
fusion and also to evaluate effects FGFR3:TACC3 overexpression on other cell charac-
teristics. In addition, inhibition of FGFR in these overexpressed cell lines with JNJ-
42756493 inhibitor was studied. Preliminary clinical trials with JNJ-42756493 inhibitor 
have shown promising results with reduction of tumor size and improving clinical out-
come (Di Stefano et al., 2015). 
10.1 Expression of FGFR3:TACC3 is increasing proliferation of 
the cells 
This study showed that FGFR3:TACC3 expressing cells are proliferating faster than con-
trol cells (Figure 12). This same effect was shown earlier by Parker et al. (2013). This 
result suggests that our stably transfected fusion positive cells behave like was expected 
and can be used as an in vitro model for FGFR3:TACC3 fusion in glioblastoma. Increased 
proliferation of FGFR3:TACC3 fusion positive cells suggests that fusion is somehow 
over-activating tyrosine kinase receptor. This is seen in Western results, where phosphor-
ylation of FGFR is seen mainly in over-expressed samples and only small phosphoryla-
tion is seen in control samples (Figures 19 and 20).  
Two main downstream pathways of FGFR are MAPK and PIK3 signaling pathways, of 
which MAPK signaling pathway is mainly responsible for proliferation of the cells. PI3K 
is responsible for avoiding apoptosis, but the signaling pathways do have some cross talk 
and for example in migration, both signaling pathways are activated. (Wesche, Haglund, 
& Haugsten, 2011) Fusion has clear effect on proliferation, but not on other cellular mech-
anisms suggesting that at least MAPK pathways is activated by FGFR3:TACC3. In fact, 
Western blotting results in this study showed increased phosphorylation of ERK and de-
creased expression of phosphorylated AKT in FGFR3:TACC3 cells after stimulation with 
FGF. Same increase in phosphorylation of ERK was seen in FGFR3 cells and control 2 
cells, however control cells had air bubble in the ERK band at 30 min time point (Figure 
19a), which has lowered the intensity value of total ERK. This will lead to increased value 
of pERK/ERK at that time point, so difference seen in ERK phosphorylation on control 
2 is not as significant on reality as it shows in the intensity plot (Figure 19b). Decrease in 
AKT phosphorylation was only seen in fusion positive samples. Overall expression level 
of pERK was higher in FGFR3 expressing cells.  
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No significant difference was seen in colony formation and migration between fusion 
positive and control cells. Figure 18 shows that FGFR3:TACC3 cells have higher per-
centage of apoptotic cells than other samples and percentage of necrotic cells is lower. 
Number of viable cells in FGFR3:TACC3 cells is similar with two control samples and 
higher than in FGFR3 cells. Apoptosis is determined as a programmed process where cell 
goes to a highly regulated and controlled cell death whereas necrosis is more passive 
process of cell death activated by outer signals. However, in the absence of phagocytic 
cells that are present in the tissues, apoptotic cells will start to lose their membrane integ-
rity and become necrotic (Fink & Cookson, 2005). In our survival experiments, necrotic 
cells are therefore a combination of cells that have started as necrotic cells and cells that 
have first gone through apoptosis and then proceeded to necrotic stage. This suggests that 
fusion positive cells have more active control mechanisms, and more cells are going 
through controlled apoptosis and cells are reaching the necrotic stage slower than in other 
samples. PI3K pathway is mainly responsible of avoiding apoptosis in the cells (Wesche 
et al., 2011). In fusion positive cells phosphorylation of AKT is highest after starvation 
and decreased after stimulation with FGF (Figure 19), which could mean that in stressful 
situations FGFR3:TACC3 is avoiding apoptosis well. Control 2 had slightly similar acti-
vation pattern of pAKT, but FGFR3 cells and control 5 cells had opposite effect. Overall 
level of AKT phosphorylation was highest in FGFR3 cells.   
Fusion protein is formed so that kinase domain of an FGFR3 is fused together with di-
merization domain of TACC3. Because the fusion happens in intracellular side of the cell 
membrane, normal down-regulation of receptors, that happens in the cell surface is 
evaded and this will result in on-going signaling with lowered negative feedback. 
(Wesche et al., 2011) It is possible that FGFR3:TACC3 fusion has also other downstream 
effects that are not dependent on the tyrosine kinase activity. One interesting effect of 
fusion was found on the study of Sarkar et al. (2017) that focused on FGFR3’s fusion 
partner TACC3. TACC3 is an important regulator of mitotic spindle on cell division. 
TACC3 domain of FGFR3:TACC3 fusion is shown to recruit endogenous TACC3 from 
the mitotic spindle causing reduction in normal TACC3 levels and dysregulation of mi-
totic spindle. This will lead to mitotic defects in cancer cells and this mechanism is sug-
gested to work together with FGFR3:TACC3 signaling affecting the oncogenic nature of 
the fusion. It is unclear how this affects tumor progression, but it is possible that mitotic 
defects caused by the fusion could be one reason why FGFR inhibitors have been seen in 
clinical trials to gain treatment resistance. (Sarkar, Ryan, & Royle, 2017)  
10.2 FGFR3 expressing cells have lowered proliferation capabil-
ity  
In this study FGFR3 over-expressing cells showed lowered proliferation compared to 
control and fusion positive cells (Figure 12). Furthermore, results show that colony for-
mation capability is lowered with FGFR3 over-expression (Figure 15). Survival studies 
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showed that FGFR3 has higher percentage of apoptotic and necrotic cells than other cell 
types (Fig. 18). According to these results it seems like glioblastoma cells expressing 
FGFR3 do not survive as well as other cell lines. Parker et al (2013) showed in their in 
vivo mice studies that mice injected with FGFR3 expressing cells had similar survival 
than mice injected with cells transfected with empty vector, however mice injected with 
high-expressing FGFR3:TACC3 clone had significantly lowered survival time. Our in 
vitro proliferation results are in line with these results shown earlier.   
Parker et al. (2013) studied also in vitro proliferation of transfected cells and showed 
increased proliferation with wild type FGFR3 compared to control cells. This is contro-
versial result compared to our proliferation results, where wild type FGFR3 was suppress-
ing proliferation. It needs to be considered, that cell clone itself is proliferating slower 
and FGFR3 over-expression is not the reason for our obtained results. Our results show 
also clear differences between cell characteristics of two controls in almost all experi-
ments. If the two clones of control cells that are transfected similarly with empty vector, 
are behaving so differently, it is challenging to draw conclusions on behavior of FGFR3 
and FGFR3:TACC3 over-expressed clones. Results in this study do show some evidence 
on oncogenic nature of FGFR3:TACC3 and suppressive nature of FGFR3. However, it 
needs to be considered how much of these behaviors can be explained with original cell 
clones just behaving differently. There might be some other mechanism than FGFR3 or 
FGFR3:TACC3 over-expression, which is affecting cell mechanisms of different clones.  
In Western blotting results, wild type FGFR3 shows clearly higher activation of down-
stream signaling pathways than other cell lines (Figure 19). FGFR3 expressing cells also 
seem to be active regardless of the starvation. Controls 2 and 5 were selected to the ex-
periments because control 2 resembles FGFR3:TACC3 and is proliferating faster. Control 
5 on the other hand is proliferating slower and resembles more FGFR3.  In contrast to 
FGFR3, control 5 clone has low overall expression of pERK and pSTAT3. Low down-
stream activation might explain slower proliferation of this clone. FGFR3 expressing 
clone is proliferating slowly even though its downstream proteins are expressed well 
which could suggest that higher downstream activation seen in FGFR3 cell line is FGFR3 
over-expression mediated.  
10.3 Inhibition of FGFR in FGFR3:TACC3 cells is decreasing 
proliferation 
Inhibition of FGFR3 showed lowered proliferation on FGFR3:TACC3 fusion cells but 
not with other cells (Figure 13). Our experiments also showed minor effect of inhibition 
on proliferation of control cell lines.  Inhibition had conflicting results on FGFR3:TACC3 
and FGFR3 cells survival. Inhibition seems to be slightly lowering number of viable cells 
in FGFR3 and control 2 cell lines but not with FGFR3:TACC3 cells. This is counter effect 
to that seen in viability studies, where inhibition lowered number of viable cells in 
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FGFR3:TACC3 over-expressing cells, but not with FGFR3 cells. This could mean that 
inhibition is targeting also FGFR3, but proliferation is so much slower that significant 
differences of inhibition on proliferation is not seen in MTT viability experiment. MTT 
viability assay measures also more cell activity than number of cells. FGFR3:TACC3 
cells might have more active metabolism, since they are proliferating faster and inhibition 
can be targeting something in the metabolism that is not as active on FGFR3 expressing 
cells. Inhibition was added to the cells only 24h prior to analysis, so clear effect on cell 
survival might not been seen yet in that incubation time. Furthermore, this assay was done 
only once with inhibition, so effect seen might only be normal variation of cells.  
Early clinical trials have shown that fusion positive tumors respond to inhibitor treatment 
with partially shrinking, but during the treatment tumors gain treatment resistance and 
restart the tumor progression (Di Stefano et al., 2015; Dienstmann et al., 2014; Perera et 
al., 2014). Furthermore, it has been shown that fusion positive tumors have heterogeneous 
FGFR3 expression. All the cells in fusion positive GBM tumors do not express 
FGFR3:TACC3 fusion but there are also cells in the tumors that are negative for this 
fusion. (Granberg et al., 2017). Portions of fusion negative cells in tumor might explain 
effects seen in preclinical trials with fusion positive tumors treated with FGFR inhibitor. 
Cell models used in this experiment have also some amount of fusion negative cells in 
them. This could have effect on inhibitor response as well.  
Clear decreasing effect of inhibition on FGFR phosphorylation was seen with both 
FGFR3 and FGFR3:TACC3 cells (Figure 20). Control cells without overexpression had 
none or only very low phosphorylation of FGFR. FGF stimulation and JNJ-42756493 
inhibition have opposite effects on FGFR phosphorylation on overexpressed cells, since 
stimulation is increasing phosphorylation and inhibition is decreasing phosphorylation of 
FGFR.  
In FGF simulation experiment some FGFR phosphorylation was seen also in non-glyco-
sylated FGFR on control 2. FGFR3 expression was not seen in control 2, so this suggest 
that some other FGFR might be present in this control sample. Since JNJ-42756493 in-
hibitor is not specific for FGFR3 but is targeting all FGFRs, it is possible that it will have 
effect on controls as well, if the control cells express some other FGFR. This could ex-
plain variation in inhibitory results in this study and also differences between behavior of 
two controls. Therefore, we are planning to check expression of other FGFRs (FGFR1, 
2, 4 and FGFRL1) from all the cell lines. Phosphorylation of FGFR seen on control sam-
ples in FGF stimulation experiment proposed that there might be phosphorylation of 
FGFR in inhibitor response experiment as well, even though figure 19 showed no clear 
changes in phosphorylation level of control samples. Appendix 2 shows longer exposure 
for pFGFR detection in control cell lines and band intensities for control samples meas-
ured with Image J. Expression of pFGFR is so low on control cells that even with longer 
exposure effects of inhibition are challenging to asses, but it seems like phosphorylation 
of FGFR in control samples does not seem to be lowered due to inhibition. 
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Inhibition had slightly decreasing effect on phosphorylation of AKT in FGFR3:TACC3, 
FGFR3 and control 2 samples in 2h and in 24h time points (Figure 20). Activation pattern 
in all other downstream targets is similar for inhibitor treated versus control treated sam-
ples. Phosphorylation of ERK is decreasing during time and phosphorylation of STAT3 
increasing during time. Because differences between control and inhibitor treated cells is 
not seen, media change that was done at the beginning of the experiment at 0 h time point 
is probably causing these seen changes in ERK and STAT3 phosphorylation.  
Despite the clear decrease in FGFR phosphorylation due to inhibition seen in this exper-
iment on both FGFR3 and FGFR3:TACC3 over-expressed cell lines, effect of inhibition 
on cellular mechanisms was small. Downstream signaling expression is not highly 
changed due to inhibition, which is suggesting that cells are using other tyrosine kinase 
receptors to control downstream signaling so inhibition does not have that much effect on 
them. Crosstalk between different tyrosine kinase receptors is seen in many different stud-
ies and can be facilitated through downstream signaling without affecting receptors them-
selves.  
Cell lines used in these experiments were stable overexpression cell lines of 
FGFR3:TACC3 fusion and FGFR3, so their expression in cells is overemphasized in 
these lines. Inhibition of these overexpression proteins may not be as efficient as it could 
be in primary cell lines. Furthermore, SNB19 cell line is commercial cell line that has 
been cultured for long times. Cell line has developed quite much since the time it was 
harvested from patient in 1980 (chapter 7.5). This cell line has probably stabilized signal-
ing routes that are optimal for culture conditions and continuous stimulation with serum. 
They may have higher expression of other tyrosine kinase receptors and their downstream 
targets and may not resemble GBM tumor as well as primary cell lines would. This could 
be the reason of only minor effects that were seen in downstream signaling due to inhibi-
tion. Effects of inhibition seen in these overexpression cell lines will be validated with 
primary cell lines later.  
10.4 Experimental aspects 
Most of the experiments were repeated at least three times. There was a slight variance 
seen between parallel experiments suggesting that experimental protocols were not stand-
ardized enough. In proliferation assay, outermost wells had often lower absorbance than 
other wells. Cells were divided to multi-well plate using multi-well pipet, so it is possible 
that multi pipet has some differences between tips and the outermost tips don’t take 
enough liquid in. Cells can also be unevenly distributed in the solution, even though they 
were mixed between the pipetting. Both of these would cause variations in the cell num-
ber in parallel wells and standard deviations might be higher. However, procedures were 
done similarly to all cell lines, so it could be assumed that error is similar in all the cell 
lines.  
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MTT is widely used for the cell viability studies, but it has some issues that are ques-
tioned. It is known to cause cytotoxicity and it is not known how the incubation times in 
MTT are affecting cell viability on different cell clones. MTT assay has also multiple 
steps, because it needs to be solubilized after incubation. Multiple steps increase the pos-
sibility of errors in pipetting and removal of fluids. Issues in MTT assay include the fact 
that it reflects more to on cell metabolism of viable cells than on number of viable cells. 
For instance, cell confluence can have effect on cell metabolism and cause errors in the 
absorbance values. (Riss et al., 2004; Riss, 2014) In these experiments cells were seeded 
so that they would not reach the full confluence, but FGFR3:TACC3 fusion was prolifer-
ating fastest, so it reached more confluent monolayer than others.  
In colony formation assay, cells are diluted to very low concentration so they can be di-
vided to wells as a single cells suspension. When working with very low concentrations, 
it is possible that cells in suspension pipetted to the wells are not divided equally and 
number of cells in the well can therefore vary. When wanted cell number on wells is so 
low, even some small differences between wells equals significant percentage in differ-
ence. Furthermore, some air bubbles in media can move cells to cluster in a certain part 
of the well closer to each other before they have attached. If the cells are not properly 
attached as single cells, their signaling with each other may affect colony formation.  
Parallel experiments also showed that SNB19 cells are not behaving similarly in every 
experiment. This was seen especially in wound healing assay, where results varied a lot 
depending on confluence of cells at the beginning of the experiment. Even though same 
number of cells was seeded to parallel wells, cells would cluster to the edges or in the 
middle of the plate. Cells also migrate actively after plating, which also affects their po-
sition and confluence. Therefore, overall confluence was not same in all parallel wells. 
Cells are using autocrine and paracrine signaling to affect the behavior of themselves or 
neighboring cells. Signaling efficiency is dependent on cell confluence, since more con-
fluent are affected more by paracrine signaling. (Alberts, Wilson, & Hunt, 2014) Another 
important cell signaling method in cell culture is signaling through cell-cell junctions. 
Cells will communicate with neighboring cells with small molecules like ions and sec-
ondary messengers that move through narrow pores between two cells called gap junc-
tions. Confluence of cells is increasing cell signaling also via these gap junctions. (Al-
berts, 2009) These different confluence dependent signals have great effect on prolifera-
tion and migrations of the cells. Differences in confluence between parallel wells was 
compensated by plating more cells on those lines that did not seem to be as confluent at 
the beginning of wound healing assay, but even with compensation some differences were 
seen. 
Stable transfection had been used for the cell lines in this experiment to introduce gene 
into the cell for long time. But even with selection antibiotic, expression of over-ex-
pressed gene can be lost from the cells over long culturing times (Appendix 1). Chromatin 
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modifications in DNA can affect expression of integrated protein in different clones (Dal-
ton & Barton, 2014). Furthermore, it is known that even stably transfected cell lines have 
instability of the integrated protein, meaning that its expression is lost in the cells. Insta-
bility can be caused by instability of the genome and for example some genes encoding 
integrated protein can be lost. Furthermore, cells that are not expressing integrated ge-
nome can have growth advantage over those that express the gene. (Barnes et al., 2003). 
It is also possible that only section marker has integrated to the genome, but studied gene 
has not. These aspects can explain lower expression of FGFR3 in other cell clones (Fig 
11).   
Results of wound healing assay was analyzed using Image J wound healing tool. This 
tool would recognize the edges of the scratch and measure the area of scratch. SNB19 
cells are very transparent and when they had migrated, different cell clones had very dif-
ferent morphologies. Appendix 3 shows wound healing images at 21h time point for all 
the cell lines. FGFR3 expressing clone is spreading more widely to the platform than 
FGFR3:TACC3 expressing clone. Also some of the cells in the images are difficult to 
detect from the platform due to their transparency.  These aspects were affecting the Im-
age J wound heling tool so that it could not always separate edges of the cells, from the 
bottom of the plate creating possible errors in image analysis. If error was seen in the 
analysis, analysis was repeated by reducing transparency of cells with enhancing contrast 
of the picture or by measuring scratch area by hand drawn edges. This potentially reduced 
the error caused by Image J analysis.  
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11. CONCLUSION 
To sum up, FGFR3:TACC3 over-expressed clone was proliferating faster and FGFR3 
slower than control cells. Lower colony formation capability was also seen in FGFR3 
expressing cells. These results are consistent with the suggestion that fusion might be 
increasing proliferation in GBM and wild type FGFR3 could be suppressive in cells. In-
hibition was suppressing growth of FGFR3:TACC3 cell line. Observed effect of inhibi-
tion on other cell mechanisms, however, were small and inconsistent. Western blotting 
showed clear decrease in phosphorylation of FGFR after inhibition in fusion positive and 
wild type FGFR cells and some minor effects on downstream signaling were also seen. 
Based on these results it is challenging to draw conclusions on inhibition mechanism in 
GBM cells, but it seems likely that effect of inhibition in vitro is somehow compensated 
in the cells. Cell lines used in this experiment were overexpression cell line of 
FGFR3:TACC3 and FGFR3, which may affect results seen in inhibition efficiency. More 
information is needed on how inhibition is affecting fusion positive cells and whether 
cells will counterbalance inhibition of FGFR signaling with some alternative signaling 
methods.  
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APPENDIX 1: AFFECTS OF CULUTURE TIME ON PERCENTAGE 
OF FGFR3 POSITIVE CELLS IN SAMPLES  
 
Figure 1. Percentages of FGFR3 positive cells detected with immunohisto-
chemical staining after 5 weeks of culturing (A). Percentages of FGFR3 
positive cells calculated with microscope in over-expressed cell lines (B).  
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APPENDIX 2: AFFECTS OF INHIBITION ON FGFR PHOSHORY-
LATION ON CONTROL SAMPLES 
 
Figure 2.  Long exposure Western image of phosphorylated FGFR from inhibitor 
treated and control samples after 30min, 2h and 24h treatment and loading con-
trol GAPDH (A). Band intensities of a two control samples as a percent of 
GAPDH control (B). Intensities are measured as a mean gray value of bands. 
Since FGFR3:TACC3 and FGFR3 expressing control treated cells have so high 
expression with this long exposure, their intensity values were excluded from B.  
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APPENDIX 3: MORPHOLOGY OF THE CELLS 
 
Figure 3.   Wound healing images of all cell lines at 21h time point. Some differ-
ences between morphology of the cell is shown. Especially FGFR3 expressing 
cells are spreading more widely to the surface, than FGFR3:TACC3 expressing 
cells. All images were plated 160 000 cell/well and magnification of microscope 
on images is 5x.  
